Rimini Street (RMNI) 10-Q 4 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Aug. 02, 2021
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-37397
Entity Registrant Name	Rimini Street, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4880301
Entity Address, Address Line One	3993 Howard Hughes Parkway
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89169
City Area Code	(702)
Local Phone Number	839-9671
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		85,764,000
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001635282
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RMNI
Security Exchange Name	NASDAQ
Public Units
Document Information [Line Items]
Title of 12(b) Security	Public Units, each consisting of one share of CommonStock, $0.0001 par value, and one-half of one Warrant
Trading Symbol	RMNIU
Warrant
Document Information [Line Items]
Title of 12(b) Security	Warrants, exercisable for one share of Common Stock, $0.0001 par value
Trading Symbol	RMNIW

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 110,387	$ 87,575
Restricted cash	334	334
Accounts receivable, net of allowance of $960 and $723, respectively	85,665	117,937
Deferred contract costs, current	14,722	13,918
Prepaid expenses and other	15,593	13,456
Total current assets	226,701	233,220
Long-term assets:
Property and equipment, net of accumulated depreciation and amortization of $12,123 and $10,985, respectively	4,465	4,820
Operating lease right-of-use assets	15,772	17,521
Deferred contract costs, noncurrent	21,839	21,027
Deposits and other	1,717	1,476
Deferred income taxes, net	1,630	1,871
Total assets	272,124	279,935
Current liabilities:
Accounts payable	4,427	3,241
Accrued compensation, benefits and commissions	38,650	38,026
Other accrued liabilities	15,926	21,154
Operating lease liabilities, current	4,055	3,940
Deferred revenue, current	229,768	228,967
Total current liabilities	292,826	295,328
Long-term liabilities:
Deferred revenue, noncurrent	35,870	27,966
Operating lease liabilities, noncurrent	14,495	15,993
Accrued PIK dividends payable	647	1,193
Liability for redeemable warrants	3,092	2,122
Other long-term liabilities	2,288	2,539
Total liabilities	349,218	345,141
Commitments and contingencies (Note 8)
Redeemable Series A Preferred Stock:
Authorized 180 shares; issued and outstanding 87 shares and 155 shares as of June 30, 2021 and December 31, 2020, respectively. Liquidation preference of $87,155, net of discount of $8,020 and $154,911, net of discount of $17,057, as of June 30, 2021 and December 31, 2020, respectively.	79,135	137,854
Stockholders’ deficit:
Preferred stock; $0.0001 par value. Authorized 99,820 shares (excluding 180 shares of Series A Preferred Stock); no other series has been designated	0	0
Common stock; $0.0001 par value. Authorized 1,000,000 shares; issued and outstanding 85,704 and 76,406 shares as of June 30, 2021 and December 31, 2020, respectively	9	8
Additional paid-in capital	143,801	98,258
Accumulated other comprehensive loss	(2,262)	(318)
Accumulated deficit	(297,777)	(301,008)
Total stockholders' deficit	(156,229)	(203,060)
Total liabilities, redeemable preferred stock and stockholders' deficit	$ 272,124	$ 279,935

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for accounts receivable	$ 960	$ 723
Accumulated depreciation and amortization	$ 12,123	$ 10,985
Redeemable preferred stock, shares authorized (shares)	180,000	180,000
Redeemable preferred stock, shares issued (shares)	87,000	155,000
Redeemable preferred stock, shares outstanding (shares)	87,155	155,000
Redeemable preferred stock, liquidation preference	$ 87,155	$ 154,911
Redeemable preferred stock, discount	$ 8,020	$ 17,057
Preferred stock, par value (USD per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (shares)	99,820,000	99,820,000
Common stock, par value (USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (shares)	85,704,000	76,406,000
Common stock, shares outstanding (shares)	85,704,000	76,406,000

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 91,614	$ 78,402	$ 179,509	$ 156,434
Cost of revenue	34,595	30,437	68,431	60,636
Gross profit	57,019	47,965	111,078	95,798
Operating expenses:
Sales and marketing	33,157	26,836	63,540	55,248
General and administrative	16,494	13,133	33,097	25,134
Impairment charge related to operating right of use assets	0	0	393	0
Litigation costs and related recoveries:
Professional fees and other costs of litigation	2,786	2,722	7,549	5,474
Insurance costs and recoveries, net	0	141	0	1,062
Litigation costs and related recoveries, net	2,786	2,863	7,549	6,536
Total operating expenses	52,437	42,832	104,579	86,918
Operating income	4,582	5,133	6,499	8,880
Non-operating income and (expenses):
Interest expense	(38)	(12)	(85)	(25)
Gain (loss) on change in fair value of redeemable warrants	3,698	(546)	(970)	(546)
Other income (expenses), net	(496)	(567)	276	(785)
Income before income taxes	7,746	4,008	5,720	7,524
Income tax expense	(939)	(1,084)	(2,489)	(2,055)
Net income	6,807	2,924	3,231	5,469
Other comprehensive income:
Foreign currency translation gain (loss)	420	402	(1,944)	(411)
Comprehensive income	7,227	3,326	1,287	5,058
Net loss attributable to common stockholders	$ (4,846)	$ (3,763)	$ (14,691)	$ (7,848)
Net loss per share attributable to common stockholders:
Basic (usd per share)	$ (0.06)	$ (0.06)	$ (0.18)	$ (0.12)
Diluted (usd per share)	$ (0.06)	$ (0.06)	$ (0.18)	$ (0.12)
Weighted average number of shares of Common Stock outstanding:
Weighted average number of shares outstanding, basic (shares)	85,343	68,290	82,056	68,076
Weighted average number of shares outstanding, diluted (shares)	85,343	68,290	82,056	68,076

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Series A Preferred Stock	Common Stock	Additional Paid-in Capital	Additional Paid-in CapitalSeries A Preferred Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit	March 2021 OfferingCommon Stock	March 2021 OfferingAdditional Paid-in Capital
Beginning balance (shares) at Dec. 31, 2019			67,503
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)			564
Restricted stock units vested (shares)			463
Issuance of common stock (shares)								0
Ending balance (shares) at Jun. 30, 2020			68,530
Stockholders' deficit, beginning of period at Dec. 31, 2019	$ (223,321)		$ 7	$ 90,695		$ (1,429)	$ (312,594)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash			0	556
Restricted stock units vested			0	0
Issuance of Common Stock in March 2021 Offering, net								$ 0	$ 0
Accretion related to redemption of Series A Preferred Stock		$ 0			$ 0
Make-whole dividends related to redemption of Series A Preferred Stock		0			0
Return on repurchase of Series A Preferred Stock shares		0			0
Stock based compensation expense				3,236
Accretion of discount on Series A Preferred Stock				(3,114)
Accrued dividends on Series A Preferred Stock:
Payable in cash				(7,849)
Payable in kind				(2,354)
Foreign currency translation gain (loss)	(411)					(411)
Net income	5,469						5,469
Stockholders' deficit, end of period at Jun. 30, 2020	(227,788)		$ 7	81,170		(1,840)	(307,125)
Beginning balance (shares) at Mar. 31, 2020			68,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)			260
Restricted stock units vested (shares)			238
Issuance of common stock (shares)								0
Ending balance (shares) at Jun. 30, 2020			68,530
Stockholders' deficit, beginning of period at Mar. 31, 2020	(226,405)		$ 7	85,879		(2,242)	(310,049)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash			0	252
Restricted stock units vested			0	0
Issuance of Common Stock in March 2021 Offering, net								$ 0	0
Accretion related to redemption of Series A Preferred Stock		0			0
Make-whole dividends related to redemption of Series A Preferred Stock		0			0
Return on repurchase of Series A Preferred Stock shares		0			0
Stock based compensation expense				1,726
Accretion of discount on Series A Preferred Stock				(1,567)
Accrued dividends on Series A Preferred Stock:
Payable in cash				(3,939)
Payable in kind				(1,181)
Foreign currency translation gain (loss)	402					402
Net income	2,924						2,924
Stockholders' deficit, end of period at Jun. 30, 2020	(227,788)		$ 7	81,170		(1,840)	(307,125)
Beginning balance (shares) at Dec. 31, 2020			76,406
Ending balance (shares) at Mar. 31, 2021			85,140
Stockholders' deficit, beginning of period at Dec. 31, 2020	(203,060)		$ 8	98,258		(318)	(301,008)
Stockholders' deficit, end of period at Mar. 31, 2021	$ (154,495)		$ 9	152,762		(2,682)	(304,584)
Beginning balance (shares) at Dec. 31, 2020			76,406
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)	801		800
Restricted stock units vested (shares)			748
Issuance of common stock (shares)								7,750
Ending balance (shares) at Jun. 30, 2021			85,704
Stockholders' deficit, beginning of period at Dec. 31, 2020	$ (203,060)		$ 8	98,258		(318)	(301,008)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash			0	3,113
Restricted stock units vested			0	0
Issuance of Common Stock in March 2021 Offering, net								$ 1	55,641
Accretion related to redemption of Series A Preferred Stock		5,673			(5,673)
Make-whole dividends related to redemption of Series A Preferred Stock		(2,343)			(2,343)
Return on repurchase of Series A Preferred Stock shares		(38)			(38)
Stock based compensation expense				4,711
Accretion of discount on Series A Preferred Stock				(2,277)
Accrued dividends on Series A Preferred Stock:
Payable in cash				(5,839)
Payable in kind				(1,752)
Foreign currency translation gain (loss)	(1,944)					(1,944)
Net income	3,231						3,231
Stockholders' deficit, end of period at Jun. 30, 2021	(156,229)		$ 9	143,801		(2,262)	(297,777)
Beginning balance (shares) at Mar. 31, 2021			85,140
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)			84
Restricted stock units vested (shares)			480
Issuance of common stock (shares)								0
Ending balance (shares) at Jun. 30, 2021			85,704
Stockholders' deficit, beginning of period at Mar. 31, 2021	(154,495)		$ 9	152,762		(2,682)	(304,584)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash			0	201
Restricted stock units vested			0	0
Issuance of Common Stock in March 2021 Offering, net								$ 0	$ 13
Accretion related to redemption of Series A Preferred Stock		5,673			(5,673)
Make-whole dividends related to redemption of Series A Preferred Stock		(2,343)			(2,343)
Return on repurchase of Series A Preferred Stock shares		$ 0			$ 0
Stock based compensation expense				2,478
Accretion of discount on Series A Preferred Stock				(804)
Accrued dividends on Series A Preferred Stock:
Payable in cash				(2,179)
Payable in kind				(654)
Foreign currency translation gain (loss)	420					420
Net income	6,807						6,807
Stockholders' deficit, end of period at Jun. 30, 2021	$ (156,229)		$ 9	$ 143,801		$ (2,262)	$ (297,777)

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical) - Series A Preferred Stock - shares	Mar. 11, 2021	Aug. 18, 2020	Jun. 20, 2019	Mar. 07, 2019	Jul. 19, 2018	Jun. 30, 2021
Sale of stock (shares)	60,000	60,000
Private Placement
Sale of stock (shares)			3,500	6,500	140,000	60,000

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 3,231	$ 5,469
Adjustments to reconcile net income to net cash provided by operating activities:
Loss on change in fair value of redeemable warrants	970	546
Stock-based compensation expense	4,711	3,236
Depreciation and amortization	1,174	886
Deferred income taxes	165	33
Impairment charge related to operating right of use assets	393	0
Amortization and accretion related to operating right of use assets	3,100	3,047
Other	0	8
Changes in operating assets and liabilities:
Accounts receivable	31,971	46,457
Prepaid expenses, deposits and other	(2,380)	3,777
Deferred contract costs	(1,616)	(1,335)
Accounts payable	1,180	2,361
Accrued compensation, benefits, commissions and other liabilities	(5,541)	(5,583)
Deferred revenue	9,804	(14,658)
Net cash provided by operating activities	47,162	44,244
CASH FLOWS USED IN INVESTING ACTIVITIES:
Capital expenditures	(832)	(725)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds related to issuance of Common Stock from March 2021 Offering	56,965	0
Payments for professional fees related to issuance of Common Stock from March 2021 Offering	(1,243)	0
Payments to repurchase shares of Series A Preferred Stock	(68,951)	0
Payments of cash dividends on Series A Preferred Stock	(9,891)	(7,805)
Principal payments on capital leases	(218)	(100)
Proceeds from exercise of employee stock options	3,112	557
Net cash used in financing activities	(20,226)	(7,348)
Effect of foreign currency translation changes	(3,292)	(1,554)
Net change in cash, cash equivalents and restricted cash	22,812	34,617
Cash, cash equivalents and restricted cash at beginning of period	87,909	38,388
Cash, cash equivalents and restricted cash at end of period	110,721	73,005
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	83	24
Cash paid for income taxes	2,038	1,464
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Underwriter discounts and commissions	2,948	0
Underwriter expenses	1,050	0
Accrued professional fees related to the issuance of Common Stock	79	0
Accrued cash dividends	2,186	3,939
Accrued PIK dividends	647	1,182
Accretion of discount on Series A Preferred Stock	2,277	3,114
Issuance of Series A Preferred Stock for PIK dividends	$ 2,244	$ 2,323

NATURE OF BUSINESS AND BASIS OF

NATURE OF BUSINESS AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NATURE OF BUSINESS AND BASIS OF PRESENTATION Nature of Business Rimini Street, Inc. (the “Company”) is a global provider of enterprise software support services. The Company’s subscription-based software support products and services offer enterprise software licensees a choice of solutions that replace or supplement the support products and services offered by enterprise software vendors. Basis of Presentation and Consolidation The unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). All significant intercompany balances and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, certain information and footnote disclosures required by U.S. GAAP for complete financial statements have been condensed or omitted in accordance with such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2020, included in the Company’s 2020 Annual Report on Form 10-K as filed with the SEC on March 3, 2021 and as subsequently amended on May 10, 2021 (as amended, the “2020 Form 10-K/A”). The accompanying condensed consolidated balance sheet and related disclosures as of December 31, 2020 have been derived from the Company’s audited financial statements. The Company’s financial condition as of June 30, 2021, and operating results for the three months ended June 30, 2021, are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the year ending December 31, 2021.

LIQUIDITY AND SIGNIFICANT ACCOU

LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES	LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES Liquidity As of June 30, 2021, the Company’s current liabilities exceeded its current assets by $66.1 million, and the Company recorded net income of $6.8 million for the three months ended June 30, 2021. As of June 30, 2021, the Company had available cash, cash equivalents and restricted cash of $110.7 million. As of June 30, 2021, the Company’s current liabilities included $229.8 million of deferred revenue whereby the historical costs of fulfilling the Company's commitments to provide services to its clients was approximately 38% of the related deferred revenue for the three months ended June 30, 2021. As discussed in Note 6, the Company completed a firm commitment underwritten public offering on March 11, 2021 (the “March 2021 Offering”) of 7.8 million shares of its common stock, par value $0.0001 per share (“Common Stock”), at a price of $7.75 per share for total gross proceeds of $57.0 million. Underwriter discounts and commissions were $2.9 million and the underwriter expenses were $0.2 million. The Company also incurred additional professional fees and expenses of $1.3 million as part of the transaction, resulting in net proceeds from the March 2021 Offering of approximately $55.7 million. The Company had previously completed a firm commitment underwritten public offering on August 18, 2020 (the “August 2020 Offering”) of 6.1 million shares of its Common Stock at a price of $4.50 per share for total gross proceeds of $27.5 million. Underwriter discounts and commissions were $1.7 million and the underwriter expenses were $0.1 million. The Company also incurred additional professional fees of $0.6 million as part of the transaction, resulting in net proceeds from the August 2020 Offering of approximately $25.1 million. On April 16, 2021, the Company redeemed 60,000 shares of its 13.00% Series A Preferred Stock at an aggregate redemption price of $62.3 million. The Company funded the partial redemption with the proceeds from the March 2021 Offering and the August 2020 Offering, which raised aggregate net proceeds of approximately $80.8 million. Additionally, the Company is obligated to make operating and financing lease payments that are due within the next 12 months in the aggregate amount of $6.4 million. In March 2020, the World Health Organization declared the outbreak of a novel strain of the coronavirus (“COVID-19”) to be a pandemic. Assuming that, after the issuance date of these financial statements, the Company’s ability to operate continues not to be significantly adversely impacted by the COVID-19 pandemic, the Company believes that current cash, cash equivalents, restricted cash, and future cash flow from operating activities will be sufficient to meet the Company’s anticipated cash needs, including cash dividend requirements, working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of these financial statements. Revision of Previously Issued Financial Statements The Company has revised certain prior period amounts on the unaudited condensed consolidated financial statements to correct a misstatement with respect to improperly classifying certain warrants to purchase approximately 6.1 million shares of the Company’s Common Stock, at $11.50 per share (the “GP Sponsor Private Placement Warrants”) as equity instead of as a warrant liability that is adjusted through charges or credits to the income statement each quarter to reflect changes in the fair value of the warrants, under the guidance of Accounting Standards Codification (“ASC”) 815-40, Contracts in Entity’s Own Equity. The Company recorded a liability for the warrants of $2.1 million as of December 31, 2020 and adjusted its additional paid-in capital and accumulated deficit accordingly. The impact to the statement of operations and statement of cash flows for both the three and six months ended June 30, 2020 was $0.5 million. There was no income tax impact associated with this revision. Total stockholders’ deficit increased by $1.3 million and $0.7 million as of June 30, 2020 and December 31, 2019, respectively. The Company has assessed the impact of improperly classifying the GP Sponsor Private Placement Warrants as equity rather than as a warranty liability that is adjusted through charges or credits to the income statement each quarter to reflect changes in the fair value of the warrants and determined the impact is not material, quantitatively or qualitatively, to the periods presented. Accordingly, the Company will adjust prior periods as those financial statements are presented for comparative purposes in future filings. See Note 11 for additional information regarding the assumptions made to determine the fair value of the GP Sponsor Private Placement Warrants as of June 30, 2021 and December 31, 2020. Use of Estimates The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, accounts receivable, valuation assumptions for stock options and leases, deferred income taxes and the related valuation allowances, and the evaluation and measurement of contingencies. To the extent there are material differences between the Company’s estimates and actual results, the Company’s future consolidated results of operation may be affected. Recent Accounting Pronouncements Recently Adopted Standards. The following accounting standards were adopted during the fiscal year 2021: In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . The guidance removes certain exceptions to the general income tax accounting principles, and clarifies and amends existing guidance to facilitate consistent application of the accounting principles. The new guidance was effective for the Company as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s Consolidated Financial Statements. In January 2020, the FASB issued ASU 2020-1 , Investments—Equity Securities (Topic 321), Investments - Equity and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) . The guidance clarifies interactions between current accounting standards on equity securities, equity method and joint ventures, and derivatives and hedging. The new guidance addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. The new guidance was effective for the Company as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s Consolidated Financial Statements.

DEFERRED CONTRACT COSTS AND DEF

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
DEFERRED CONTRACT COSTS AND DEFERRED REVENUE	DEFERRED CONTRACT COSTS AND DEFERRED REVENUE Activity for deferred contract costs for the three and six months ended June 30, 2021 and 2020 is shown below (in thousands): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Deferred contract costs, current and noncurrent, as of the beginning of period $ 34,500 $ 28,472 $ 34,945 $ 28,049 Capitalized commissions during the period 5,868 4,289 9,142 8,042 Amortized deferred contract costs during the period (3,807) (3,377) (7,526) (6,707) Deferred contract costs, current and noncurrent, as of the end of period $ 36,561 $ 29,384 $ 36,561 $ 29,384 Deferred revenue activity for the three and six months ended June 30, 2021 and 2020 is shown below (in thousands): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Deferred revenue, current and noncurrent, as of the beginning of period $ 249,997 $ 222,654 $ 256,933 $ 235,498 Billings, net 107,255 74,254 188,214 139,442 Revenue recognized (91,614) (78,402) (179,509) (156,434) Deferred revenue, current and noncurrent, as of the end of period $ 265,638 $ 218,506 $ 265,638 $ 218,506 The transaction price allocated to the remaining performance obligations represents contracted revenue that has not yet been recognized. As of June 30, 2021, the remaining transaction price included in deferred revenue was $229.8 million in current and $35.9 million in noncurrent.

OTHER FINANCIAL INFORMATION

OTHER FINANCIAL INFORMATION	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
OTHER FINANCIAL INFORMATION	OTHER FINANCIAL INFORMATION Other Accrued Liabilities As of June 30, 2021 and December 31, 2020, other accrued liabilities consist of the following (in thousands): 2021 2020 Accrued sales and other taxes $ 4,288 $ 5,213 Accrued professional fees 4,908 5,912 Accrued dividends on Redeemable Series A Preferred Stock 2,186 3,842 Current maturities of capital lease obligations 369 429 Income taxes payable 1,038 2,245 Other accrued expenses 3,137 3,513 Total other accrued liabilities $ 15,926 $ 21,154 Interest Expense

REDEEMABLE SERIES A PREFERRED S

REDEEMABLE SERIES A PREFERRED STOCK	6 Months Ended
	Jun. 30, 2021
Temporary Equity Disclosure [Abstract]
REDEEMABLE SERIES A PREFERRED STOCK	REDEEMABLE SERIES A PREFERRED STOCK 2018 Securities Purchase Agreement On July 19, 2018, the Company closed a Securities Purchase Agreement (the “2018 SPA”) with several accredited investors (the “Purchasers”) for a private placement (the “Initial Private Placement”) of (i) 140,000 shares of Series A Preferred Stock, (ii) approximately 2.9 million shares of Common Stock, and (iii) convertible secured promissory notes (the “Convertible Notes”), with no principal amount outstanding at issuance that solely collateralize amounts, if any, that may become payable by the Company pursuant to certain redemption provisions of the Series A Preferred Stock. Pursuant to the 2018 SPA, the Purchasers acquired an aggregate of 140,000 shares of Series A Preferred Stock, 2.9 million shares of Common Stock, and Convertible Notes with no principal amount outstanding as of the issuance date, for an aggregate purchase price equal to $133.0 million in cash (after taking into account a discount of $7.0 million, but before the incremental and direct transaction costs associated with the Private Placement of $4.6 million). The allocation of the net proceeds as of the closing date, along with changes in the net carrying value of the Series A Preferred Stock through June 30, 2021, are set forth below (dollars in thousands): Series A Preferred Stock Common Convertible Shares Amount Stock Notes Total Fair value on July 19, 2018: Series A Preferred Stock 140,000 $ 126,763 (1) $ — $ — $ 126,763 Common Stock — — 20,131 (2) — 20,131 Convertible Notes — — — — — Total 140,000 $ 126,763 $ 20,131 $ — $ 146,894 Relative fair value allocation on July 19, 2018 Aggregate cash proceeds on July 19, 2018 140,000 $ 114,773 (3) $ 18,227 (3) $ — $ 133,000 Incremental and direct costs — (3,994) (4) (634) (4) — (4,628) Net carrying value on July 19, 2018 140,000 $ 110,779 $ 17,593 $ — $ 128,372 _________________ (1) The liquidation preference for each share of Series A Preferred Stock on the closing date for the Initial Private Placement was $1,000 per share for an aggregate liquidation preference of $140.0 million. The estimated fair value of the Series A Preferred Stock was approximately $126.8 million on July 19, 2018, which is the basis for allocation of the net proceeds. Please refer to Note 11 for further discussion of the valuation methodology employed. (2) The fair value of the issuance of approximately 2.9 million shares of Common Stock was based on the last closing price of $6.95 per share on the date prior to closing the transaction. (3) The aggregate cash proceeds of $133.0 million on July 19, 2018 were allocated pro rata based on the fair value of all consideration issued. (4) Incremental and direct costs of the Initial Private Placement were allocated pro rata based on the fair value of all consideration issued. Such costs include financial advisory and professional fees of $2.7 million that were incurred by the Company, and due diligence and professional fees incurred by the investors of $1.9 million. At the closing, the Company used the $133.0 million of proceeds from the Initial Private Placement plus cash and cash equivalents of $2.7 million to (i) repay all outstanding indebtedness and various operating and financing fees and expenses under its former credit facility in the aggregate amount of $132.8 million, (ii) pay incremental and direct transaction costs of $2.7 million, and (iii) pay a professional services retainer of $0.2 million. In connection with the completion of the Initial Private Placement, the Company, among other customary closing actions, (i) filed a Certificate of Designations with the State of Delaware setting forth the rights, preferences, privileges, qualifications, restrictions and limitations on the Series A Preferred Stock (the “CoD”), (ii) entered into a Registration Rights Agreement with the Purchasers setting forth certain registration rights of capital stock held by the Purchasers (the “Registration Rights Agreement”), (iii) delivered a Convertible Note to each Purchaser, and (iv) entered into a Security Agreement (the “Security Agreement”) in respect of the Company’s assets collateralizing the amounts that may become payable pursuant to the Convertible Notes if certain redemption provisions of the Series A Preferred Stock are triggered in the future. March 2019 Securities Purchase Agreement On March 7, 2019, the Company entered into a securities purchase agreement (the “March 2019 SPA”) with an accredited investor for a private placement (the “March 2019 Private Placement”) of (i) 6,500 shares of Series A Preferred Stock, (ii) 134,483 shares of Common Stock, and (iii) a Convertible Note with no principal balance outstanding. The shares of Series A Preferred Stock were authorized pursuant to the CoD and are subject to the provisions set forth in an amended Security Agreement, a Convertible Note and a registration rights agreement that is substantially similar in all material respects to the Registration Rights Agreement entered into in connection with the 2018 SPA discussed above. The accredited investor in the March 2019 Private Placement is affiliated with one of the accredited investors in the Initial Private Placement. The aggregate cash proceeds from the March 2019 Private Placement were $5.8 million in cash (after an 11.0% discount or $0.7 million). The net proceeds were approximately $5.0 million after estimated transaction costs payable by the Company of $0.8 million. The transaction costs consisted of 85,000 shares of Common Stock issued to the existing holders of the Series A Preferred Stock for their consent at a cost of approximately $0.5 million and direct transaction costs of approximately $0.3 million related to due diligence and professional fees. The net proceeds were allocated based on their relative fair values at issuance of the Series A Preferred Stock and the Common Stock. The allocation of the net proceeds from the March 2019 Private Placement are set forth below (dollars in thousands): Series A Preferred Stock Common Convertible Shares Amount Stock Notes Total Fair value on March 7, 2019: Series A Preferred Stock 6,500 $ 5,313 (1) $ — $ — $ 5,313 Common Stock — — 722 (2) — 722 Convertible Notes — — — — — Total 6,500 $ 5,313 $ 722 $ — $ 6,035 Relative fair value allocation on March 7, 2019: Aggregate cash proceeds on March 7, 2019 6,500 $ 5,093 (3) $ 692 (3) $ — $ 5,785 Incremental and direct costs — (661) (4) (90) (4) — (751) Net carrying value on March 7, 2019 6,500 $ 4,432 $ 602 $ — $ 5,034 (1) The liquidation preference for each share of Series A Preferred Stock on the closing date for the March 2019 Private Placement was $1,000 per share for an aggregate liquidation preference of $6.5 million. The estimated fair value of the Series A Preferred Stock was approximately $5.3 million on March 7, 2019, which is the basis for allocation of the net proceeds. Please refer to Note 11 for further discussion of the valuation methodology employed. (2) The fair value of the issuance of approximately 134,483 shares of Common Stock was based on the closing price of $5.37 per share on the date prior to closing of the transaction. (3) The aggregate cash proceeds of $5.8 million on March 7, 2019 were allocated pro rata based on the fair value of all consideration issued. (4) Incremental and direct costs related to the March 2019 Private Placement were allocated pro rata based on the fair value of all consideration issued. Such costs included the issuance of 85,000 shares of Common Stock to the Initial Private Placement investors in the Series A Preferred Stock for their consent of approximately $0.5 million and financial advisory and professional fees that were incurred of approximately $0.3 million that were either paid or accrued directly by the Company as of March 31, 2019. June 2019 Securities Purchase Agreement On June 20, 2019, the Company entered into a securities purchase agreement (the “June 2019 SPA”) with accredited investors for a private placement (the “June 2019 Private Placement”) of (i) 3,500 shares of Series A Preferred Stock, (ii) 72,414 shares of Common Stock, and (iii) a Convertible Note with no principal balance outstanding. The shares of the Series A Preferred Stock were authorized pursuant to the CoD and are subject to the provisions set forth in an amended Security Agreement, a Convertible Note and a registration rights agreement that is substantially similar in all material respects to the Registration Rights Agreement entered into connection with the 2018 SPA discussed above. The accredited investors in the June 2019 Private Placement are not affiliated with the accredited investors in the March 2019 Private Placement or the Initial Private Placement. The aggregate cash proceeds from the June 2019 Private Placement were $3.3 million in cash (after a 5.0% discount or $0.2 million). The net proceeds were approximately $3.0 million after estimated transaction costs payable by the Company of $0.3 million. The transaction costs consisted of 35,000 shares of Common Stock issued to the existing holders of the Series A Preferred Stock for their consent at a cost of approximately $0.2 million and direct transaction costs of approximately $0.2 million related to professional fees of the investors, existing holders of Series A Preferred Stock and the Company. The net proceeds were allocated based on their relative fair values at issuance of the Series A Preferred Stock and the Common Stock. The allocation of the net proceeds from the June 2019 Private Placement are set forth below (dollars in thousands): Series A Preferred Stock Common Convertible Shares Amount Stock Notes Total Fair value on June 20, 2019: Series A Preferred Stock 3,500 $ 2,997 (1) $ — $ — $ 2,997 Common Stock — — 376 (2) — 376 Convertible Notes — — — — — Total 3,500 $ 2,997 $ 376 $ — $ 3,373 Relative fair value allocation on June 20, 2019: Aggregate cash proceeds on June 20, 2019 3,500 $ 2,954 (3) $ 371 (3) $ — $ 3,325 Incremental and direct costs — (301) (4) (38) (4) — (339) Net carrying value on June 20, 2019 3,500 $ 2,653 $ 333 $ — $ 2,986 (1) The liquidation preference for each share of Series A Preferred Stock on the closing date for the June 2019 Private Placement was $1,000 per share for an aggregate liquidation preference of $3.5 million. The estimated fair value of the Series A Preferred Stock was approximately $3.0 million on June 20, 2019, which is the basis for allocation of the net proceeds. Please refer to Note 11 for further discussion of the valuation methodology employed. (2) The fair value of the issuance of approximately 72,414 shares of Common Stock was based on the closing price of $5.19 per share on the date prior to closing of the transaction. (3) The aggregate cash proceeds of $3.3 million on June 20, 2019 were allocated pro rata based on the fair value of all consideration issued. (4) Incremental and direct costs related to the June 2019 Private Placement were allocated pro rata based on the fair value of all consideration issued. Such costs included the issuance of 35,000 shares of Common Stock to the Initial Private Placement investors in the Series A Preferred Stock for their consent of approximately $0.2 million and financial advisory and professional fees that were incurred of approximately $0.2 million that were either paid or accrued directly by the Company as of June 30, 2019. On April 16, 2021, the Company redeemed 60,000 shares of its 13.00% Series A Preferred Stock at an aggregate total redemption price of $62.3 million. The total price consisted of $60.0 million related to the face value of $1,000 per share of Series A Preferred Stock and $2.3 million or $39.05 per share of Series A Preferred Stock related to the dividends to be earned for the period from April 1, 2021 through July 18, 2021. The redeemed shares of Series A Preferred Stock, along with the dividends were recorded when the redemption offer became mandatorily redeemable on April 16, 2021. The Company funded the redemption with a portion of the proceeds from the March 2021 Offering and the August 2020 Offering, which raised aggregate net proceeds of approximately $80.7 million. On January 5, 2021, the Company entered into an agreement with certain of the holders of its Series A Preferred Stock (the “January 2021 Stock Repurchase Agreement”) to repurchase 10,000 shares of Series A Preferred Stock and the associated obligations pursuant to the Company’s Convertible Secured Promissory Notes outstanding in respect thereof (the “Note Obligations”) for an aggregate purchase price of approximately $8.95 million representing a discount to the face value of such shares of Series A Preferred Stock and no make-whole payments were required. The January 2021 Stock Repurchase Agreement contains customary representations, warranties and covenants of the parties and waivers relating to the purchased shares of Series A Preferred Stock. Upon the closing of the transactions contemplated by the January 2021 Stock Repurchase Agreement, the shares of Series A Preferred Stock purchased by the Company were retired (and the underlying Note Obligations cancelled) and are not eligible for re-issuance by the Company in accordance with the terms of the CoD. On October 30, 2020, the Company entered into an agreement (the “October 2020 Stock Repurchase Agreement”) with certain of the holders of its Series A Preferred Stock to repurchase 5,000 shares of Series A Preferred Stock and the associated Note Obligations for an aggregate purchase price of approximately $4.5 million representing a discount to the face value of such shares of Series A Preferred Stock and no make-whole payments were required. The October 2020 Stock Repurchase Agreement contains customary representations, warranties and covenants of the parties and waivers relating to the purchased shares of Series A Preferred Stock. Subsequent Event On June 18, 2021, the Company issued a notice (the “June 2021 Notice of Redemption”) to redeem the remaining shares of its 13.00% Series A Preferred Stock on July 20, 2021 at an aggregate total redemption price of $88.4 million. The total price consists of $87.8 million related to the face value of $1,000 per share of Series A Preferred Stock and $0.6 million or $6.86 per share of Series A Preferred Stock related to the dividends to be earned for the period from July 1, 2021 through July 19, 2021. The redeemed shares of the Series A Preferred Stock, along with the dividends, will be recorded on the redemption date of July 20, 2021. The Company funded the redemption with a five year term loan of $90 million, which was entered into on July 20, 2021 (the “Credit Facility”). The Credit Facility will bear interest at the London Interbank Offered Rate (“LIBOR”) plus a margin ranging from 1.75% to 2.50% and contains certain financial covenants, including a minimum fixed charge coverage ratio, a total leverage ratio, and a minimum liquidity of $20 million in U.S. cash. Annual minimum principal payments over the five year term for the Credit Facility will be 5%, 5%, 7.5%, 7.5%,and 10%, respectively, with the remaining balance due at the end of the term. The changes in the net carrying value of Series A Preferred Stock from December 31, 2020 to June 30, 2021 are set forth below (dollars in thousands): Series A Preferred Stock Shares Amount Net carrying value as of December 31, 2020 154,911 $ 137,854 Issuance of shares to settle PIK Dividends on January 4, 2021 1,193 1,193 Repurchase of 10,000 shares on January 5, 2021 (10,000) (8,913) Accretion of discount for the three months ended March 31, 2021 — 1,473 Net carrying value as of March 31, 2021 146,104 131,607 Issuance of shares to settled PIK Dividends on April 1, 2021 1,051 1,051 Redemption of 60,000 shares on April 16, 2021 (60,000) (54,327) Accretion of discount for the three months ended June 30, 2021 — 804 Net carrying value as of June 30, 2021 87,155 $ 79,135 For future calculations of earnings applicable to common stockholders, the aggregate discount applicable to the Series A Preferred Stock will be accreted using the effective interest method from the respective issuance dates through July 19, 2023 when the holders of all outstanding shares of Series A Preferred Stock were able to first elect to redeem their shares for cash. Agreements Related to Private Placement Transactions In connection with the completion of the Initial Private Placement, the Company, among other customary closing actions, (i) filed the CoD, (ii) entered into the Registration Rights Agreement, (iii) delivered a Convertible Note to each Purchaser, and (iv) entered into the Security Agreement in respect of the Company’s assets collateralizing the amounts that may become payable pursuant to the Promissory Notes if certain redemption provisions of the Series A Preferred Stock are triggered in the future. In connection with both the March 2019 Private Placement and June 2019 Private Placement, the Company entered into a securities purchase agreement, a Registration Rights Agreement, a First (March 2019) and Second (June 2019) Amendment to the Security Agreement, and issued Convertible Notes to each investor, in each case substantially in the same form as entered into by the Company in the Initial Private Placement. Certificate of Designations of the Series A Preferred Stock and Dividends The CoD authorizes the issuance of up to 180,000 shares of Series A Preferred Stock. The holders of Series A Preferred Stock are entitled to, from the respective issuance date, a cash dividend of 10.0% per annum (the “Cash Dividends”) and a payment-in-kind dividend of 3.0% per annum (the “PIK Dividends” and, together with the Cash Dividends, the “Dividends”) for the first five years following the initial June 2018 closing and thereafter all dividends accruing on such Series A Preferred Stock will be payable in cash at a rate of 13.0% per annum. The Series A Preferred Stock is classified as mezzanine equity in the Company’s consolidated balance sheet as of June 30, 2021 and December 31, 2020 since the holders have redemption rights beginning on July 19, 2023 (and earlier under certain circumstances). As required under the CoD, the Cash Dividends and PIK Dividends for the period in which the Series A Preferred Stock was outstanding during the second quarter of 2021 were settled on July 1, 2021 to holders of record on June 16, 2021. Accordingly, the Company accrued a current liability for accrued Cash Dividends through June 30, 2021 for $2.2 million. A long-term liability was recorded for $0.6 million of PIK Dividends that accrued through June 30, 2021, which were settled through the issuance of 647 shares of Series A Preferred Stock on July 1, 2021. Presented below is a summary of total and per share dividends declared through June 30, 2021 (dollars in thousands, except per share amounts): Dividends Payable in: Total Dividends Cash PIK Dividends Per Share Dividends payable as of December 31, 2020 $ 3,842 $ 1,193 $ 5,035 $ 32.50 Cash Dividends 10% per annum 3,660 — 3,660 23.40 PIK Dividends 3% per annum — 1,098 1,098 7.02 Fractional PIK shares settled for cash 47 (47) — — Less dividends settled January 4, 2021 (4,009) (1,193) (5,202) (33.26) Dividends payable as of March 31, 2021 3,540 1,051 4,591 32.14 Cash Dividends 10% per annum 2,179 — 2,179 25.00 PIK Dividends 3% per annum — 654 654 7.50 Fractional PIK shares settled for cash 7 (7) — — Less dividends settled April 1, 2021 (3,540) (1,051) (4,591) (52.68) Dividends payable as of June 30, 2021 $ 2,186 $ 647 $ 2,833 $ 32.51 The liquidation value of the Series A Preferred Stock is convertible into shares of Common Stock at an initial conversion rate of $10.00 per share for a total of 8.7 million shares of Common Stock based on 87,155 shares of Series A Preferred Stock outstanding as of June 30, 2021. Each share of Series A Preferred Stock is convertible at the holder’s option into one share of Common Stock at a conversion price equal to the quotient of (i) the Liquidation Preference (as defined below), and (ii) $10.00 (subject to appropriate adjustment in the event of a stock split, stock dividend, combination or other similar recapitalization) (the “Per Share Amount”). The Company has the right to convert outstanding shares of Series A Preferred Stock into Common Stock for the Per Share Amount after July 19, 2021, if the Company’s volume weighted average stock price for at least 30 trading days of the 45 consecutive trading days immediately preceding such conversion is greater than $11.50 per share. The Company can exercise this right to convert twice per calendar year for a maximum number of shares of Common Stock equal to the amount that has publicly traded over the 60 consecutive trading days prior to the conversion date (less any shares of Common Stock that have been issued pursuant to any such conversion during such 60-day period). The Series A Preferred Stock will become mandatorily redeemable, upon the election by the holders of a majority of the then outstanding shares, on or after July 19, 2023. Any and all of the then outstanding liquidation value of the Series A Preferred Stock plus any capitalized PIK Dividends and any unpaid accrued Cash Dividends not previously included in the Liquidation Preference (the “Redemption Amount”) is required to be repaid in full in cash on such redemption date or satisfied in the form of obligations under the Convertible Notes. Additionally, in certain circumstances the Company may require the holders of shares of the Series A Preferred Stock to convert into shares of Common Stock in lieu of cash payable upon redemption. The Series A Preferred Stock will also become mandatorily redeemable at any time upon the reasonable determination of the holders of a majority of the Series A Preferred Stock then outstanding of the occurrence of a Material Adverse Effect or the occurrence of a Material Litigation Effect (as such terms are defined in the CoD), with the Redemption Amounts payable automatically becoming payment obligations pursuant to the Convertible Notes with a concurrent cancellation of the shares of the Series A Preferred Stock, unless under certain circumstances, the Company redeems the Series A Preferred Stock for cash at such time. Prior to July 19, 2021, the Company has the right to redeem up to $80.0 million of shares of the Series A Preferred Stock for cash amounts equal to the Redemption Amount which would include a make-whole premium that provides the holders thereof with full yield maintenance as if the Series A Preferred Stock was held until July 19, 2021, provided that such redemptions are subject to certain conditions and limitations. After July 19, 2021, the Company will have the right to redeem shares of Series A Preferred Stock for a cash per share amount equal to the Redemption Amount. The holders of Series A Preferred Stock may exercise their conversion rights prior to any optional redemption. In the event of a liquidation, dissolution or winding up of the Company, the Series A Preferred Stock is entitled to a liquidation preference in the amount of the greater of (i) $1,000 plus accrued but unpaid Dividends (the “Liquidation Preference”), and (ii) the per share amount of all cash, securities and other property to be distributed in respect of the Common Stock such holder would have been entitled to receive for its Series A Preferred Stock on an as-converted basis. In the event of a liquidation, dissolution or winding up of the Company prior to July 19, 2021, the holders are entitled to a make-whole premium that provides the holders thereof with full yield maintenance as if the shares of Series A Preferred Stock were held until July 19, 2021. Until approximately 95% of the Series A Preferred Stock or Convertible Notes are no longer outstanding, the Company is restricted from incurring Indebtedness (as defined in the June 2019 SPA, March 2019 SPA and 2018 SPA), subject to certain exceptions. Registration Rights Agreement The original Registration Rights Agreement required the Company to register the resale of the shares of Common Stock and Series A Preferred Stock issued pursuant to the 2018 SPA. The Company satisfied such registration requirements in November 2018. The Registration Rights Agreements, entered into in connection with both the March 2019 and June 2019 Private Placements, required the Company to register the resale of the shares of Common Stock and Series A Preferred Stock pursuant to the March 2019 SPA and the June 2019 SPA within 120 days of the respective March 7, 2019 and June 20, 2019 closing dates. The Company satisfied all such registration requirements in July 2019. Each such Registration Rights Agreement also includes customary “piggyback” registration rights, suspension rights, indemnification, contribution, and assignment provisions.

COMMON STOCK OFFERING, RESTRICT

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS	COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS Common Stock Offerings On March 11, 2021, the Company completed the March 2021 Offering of 7.8 million shares of its Common Stock at a price of $7.75 per share for total gross proceeds of $56.9 million. Underwriter discounts and commissions were $2.9 million and the underwriter expenses were $0.2 million. The Company also incurred additional professional fees and expenses of $1.3 million as part of the transaction, resulting in net proceeds from the March 2021 Offering of approximately $55.6 million. The Company used the net proceeds from the March 2021 Offering to redeem 60,000 shares of Series A Preferred Stock. On August 18, 2020, the Company completed the August 2020 Offering of 6.1 million shares of its Common Stock at a price of $4.50 per share for total gross proceeds of $27.5 million. Underwriter discounts and commissions were $1.7 million and the underwriter expenses were $0.1 million. The Company also incurred additional professional fees of $0.6 million as part of the transaction, resulting in net proceeds from the August 2020 Offering of approximately $25.1 million. The Company used the net proceeds from the August 2020 Offering to redeem 60,000 shares of Series A Preferred Stock and for working capital and other general corporate purposes. Stock Option Plans The Company’s stock option plans consist of the 2007 Stock Plan (the “2007 Plan”) and the 2013 Equity Incentive Plan, as amended and restated in July 2017 (the “2013 Plan”). The 2007 Plan and the 2013 Plan are collectively referred to as the “Stock Plans”. On February 23, 2021, the Board of Directors authorized an increase of approximately 3.1 million shares available for grant under the 2013 Plan. For additional information about the Stock Plans, please refer to Note 8 to the Company’s consolidated financial statements for the year ended December 31, 2020, included in the 2020 Form 10-K/A. The information presented below provides an update for activity under the Stock Plans for both the three and six months ended June 30, 2021. Restricted Stock Units For the six months ended June 30, 2021, the Board of Directors granted restricted stock units (“RSUs”) under the 2013 Plan for an aggregate of approximately 1.1 million shares of Common Stock to employees and to non-employee directors of the Company. RSU grants vest over periods generally ranging from 12 to 36 months from the respective grant dates and the awards are subject to forfeiture upon termination of employment or service on the Board of Directors, as applicable. Based on the weighted average fair market value of the Common Stock on the date of grant of $7.35 per share, the aggregate fair value for the shares underlying the RSUs amounted to $8.0 million as of the grant date that will be recognized as compensation cost over the vesting period. Accordingly, compensation expense related to RSUs of approximately $2.2 million and $1.3 million was recognized for the three months ended June 30, 2021 and 2020, respectively. Compensation expense related to RSUs of approximately $4.1 million and $2.5 million was recognized for the six months ended June 30, 2021 and 2020, respectively. As of June 30, 2021, the unrecognized expense of $13.2 million net of forfeitures is expected to be charged to expense on a straight-line basis as the RSUs vest over a weighted-average period of approximately 1.8 years. Stock Options For the six months ended June 30, 2021, the Board of Directors granted stock options for the purchase of an aggregate of approximately 0.7 million shares of Common Stock at exercise prices that were equal to the fair market value of the Common Stock on the date of grant. These stock options generally vest annually for one-third of the awards and expire ten years after the grant date. The following table sets forth a summary of stock option activity under the Stock Plans for the six months ended June 30, 2021 (shares in thousands): Shares Price (1) Term (2) Outstanding, December 31, 2020 7,007 $ 5.24 5.0 Granted 665 7.61 Forfeited (65) 4.74 Expired (95) 6.45 Exercised (801) 3.87 Outstanding, June 30, 2021 (3)(4) 6,711 5.62 5.2 Vested, June 30, 2021 (3) 5,386 5.50 4.3 (1) Represents the weighted average exercise price. (2) Represents the weighted average remaining contractual term until the stock options expire. (3) As of June 30, 2021, the aggregate intrinsic value of all stock options outstanding was $8.2 million. As of June 30, 2021, the aggregate intrinsic value of vested stock options was $7.1 million. (4) The number of outstanding stock options that are not expected to ultimately vest due to forfeiture amounted to 0.2 million shares as of June 30, 2021. The following table presents activity affecting the total number of shares available for grant under the Stock Plans for the six months ended June 30, 2021 (in thousands): Available, December 31, 2020 4,037 Newly authorized by Board of Directors 3,056 Stock options granted (665) Restricted stock units granted (1,085) Expired options under Stock Plans 95 Forfeited options under Stock Plans 65 Forfeited restricted stock units under Stock Plans 105 Available, June 30, 2021 5,608 The aggregate fair value of approximately 0.7 million stock options granted for the six months ended June 30, 2021 amounted to $2.0 million, or $3.06 per stock option as of the grant date utilizing the Black-Scholes-Merton (“BSM”) method. The fair valued derived under the BSM method will result in the recognition of compensation cost over the vesting period of the stock options. For the six months ended June 30, 2021, the fair value of each stock option grant under the Stock Plans was estimated on the date of grant using the BSM option-pricing model, with the following weighted-average assumptions: Expected life (in years) 6.0 Volatility 41% Dividend yield 0% Risk-free interest rate 0.86% Fair value per common share on date of grant $7.61 As of June 30, 2021 and December 31, 2020, total unrecognized compensation costs related to unvested stock options, net of estimated forfeitures, was $2.2 million and $1.2 million, respectively. As of June 30, 2021, the unrecognized costs are expected to be charged to expense on a straight-line basis over a weighted-average vesting period of approximately 2.1 years. Stock-Based Compensation Expense Stock-based compensation expense attributable to RSUs and stock options is classified as follows (in thousands): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Cost of revenues $ 375 $ 279 $ 691 $ 563 Sales and marketing 874 637 1,601 1,260 General and administrative 1,229 810 2,419 1,413 Total $ 2,478 $ 1,726 $ 4,711 $ 3,236 Warrants On April 12, 2021, the SEC issued a Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (the “SEC Staff Statement”). Upon review of the SEC Staff Statement which addressed certain accounting and reporting considerations related to warrants similar to the Company’s GP Sponsor Private Placement Warrants and upon review of ASC 815-40, Contracts in Entity’s Own Equity, the Company determined that its GP Sponsor Private Placement Warrants should have been classified as a liability instead of equity. See Note 2 for further information regarding this revision to the Company’s consolidated financial statements. See Note 11 for information regarding the fair value of the GP Sponsor Private Placement Warrants as of June 30, 2021 and December 31, 2020.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was passed into law, amending portions of relevant U.S. tax laws. The CARES Act contains changes to corporate taxation, including among other things, adjusting net operating loss (NOL) limitations and carryback rules, refundable AMT credits, bonus depreciation and interest expense limitations. The CARES Act also provides for an Employee Retention Credit, a fully refundable payroll tax credit for certain eligible employers and the ability for all eligible employers to defer payment of the employer share of payroll taxes owed on wages paid for the period ending December 31, 2020 (such deferred payroll taxes are due in two installments: 50% by December 31, 2021 and 50% by December 31, 2022). The Company has elected to defer payroll tax payments which totaled $3.3 million as of June 30, 2021. For the three months ended June 30, 2021 and 2020, the Company’s effective tax rate was 12.1% and 27.0%, respectively. For the six months ended June 30, 2021 and 2020, the Company’s effective tax rate was 43.5% and 27.3%, respectively. The Company’s income tax expense was primarily attributable to earnings in foreign jurisdictions subject to income taxes and foreign withholding taxes. In addition, there was no tax impact associated with the loss on change in fair value of redeemable warrants for three months ended June 30, 2021. The Company did not have any material changes to its conclusions regarding

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Retirement Plan The Company has defined contribution plans for both its U.S. and foreign employees. For certain of these plans, employees may contribute up to the statutory maximum, which is set by law each year. The plans also provide for employer contributions. The Company’s matching contributions to these plans totaled $0.9 million and $0.7 million for the three months ended June 30, 2021 and 2020, respectively. The Company’s matching contributions to these plans totaled $1.7 million and $1.3 million for the six months ended June 30, 2021 and 2020, respectively. Rimini I Litigation In January 2010, certain subsidiaries of Oracle Corporation (together with its subsidiaries individually and collectively, “Oracle”) filed a lawsuit, Oracle USA, Inc. et al. v. Rimini Street, Inc. et al. (United States District Court for the District of Nevada) (the “District Court”) (“Rimini I”), against the Company and its Chief Executive Officer, Seth Ravin, alleging that certain of the Company’s processes (Process 1.0) violated Oracle’s license agreements with its customers and that the Company committed acts of copyright infringement and violated other federal and state laws. The litigation involved the Company’s business processes and the manner in which the Company provided services to its clients. After completion of a jury trial in 2015 and subsequent appeals, the final outcome of Rimini I was that Mr. Ravin was found not liable for any claims and the Company was found liable for only one claim: “innocent infringement,” a jury finding that the Company did not know and had no reason to know that its former support processes were infringing. The jury also found that the infringement did not cause Oracle to suffer lost profits. The Company was ordered to pay a judgment of $124.4 million in 2016, which the Company promptly paid and then pursued appeals. With interest, attorneys’ fees and costs, the total judgment paid by the Company to Oracle after the completion of all appeals was approximately $89.9 million. A portion of such judgment was paid by the Company’s insurance carriers. Injunction Following post-trial motions, the District Court entered a permanent injunction prohibiting the Company from using certain processes. In August 2019, the United States Court of Appeals for the Ninth Circuit (the “Court of App”) affirmed the permanent injunction issued by the District Court, while also correcting certain legal errors that narrowed the scope of the injunction. The injunction prohibits the Company from using support processes that had been found in Rimini I to “innocently” infringe certain Oracle copyrights, which the Company ceased using no later than July 31, 2014. The injunction does not prohibit the Company’s provision of support services for any Oracle product lines, but rather defines the manner in which the Company can provide support services for certain Oracle product lines. On July 10, 2020, Oracle filed a motion to show cause contending that the Company is in violation of the injunction, and the Company opposed this motion, disputing Oracle’s claims. On March 31, 2021, the District Court issued an order resolving many outstanding disputes between the parties relating to the injunction. The District Court found that the Company violated the injunction in four certain narrow instances and scheduled an evidentiary hearing for September 20, 2021 to hear evidence and argument regarding whether the Company (i) violated the injunction for certain accused conduct for which the District Court requested additional information and (ii) should be held in contempt for the instances where the District Court found a violation of the injunction, and what sanctions, if any, are appropriate. In its March 31, 2021 order, the District Court refused to consider Oracle’s claims about certain processes that were not litigated in Rimini I, and that are being litigated in the separately filed Rimini Street Inc. v. Oracle Int’l Corp. litigation (described below under the heading “Rimini II Litigation”). In April 2021, the Company filed a motion for reconsideration for two of the four injunction violations identified by the District Court (since they occurred before the injunction became effective). The District Court granted the Company’s motion for reconsideration on June 10, 2021, striking from its March 31, 2021 order its holding regarding those two violations. The Company and Oracle have filed responses to the District Court’s orders related to the contempt proceedings. At this time, the Company does not have sufficient information regarding possible damages for the contempt asserted by Oracle. As a result, an estimate of the range of loss cannot be reasonably determined. The Company believes that it has complied with the injunction, that Oracle will not be able to meet the burden to establish contempt of the injunction for the now two certain narrow instances for which the District Court found violations, that Oracle will be unable to establish additional violations of the injunction at the September 2021 hearing and that an award for sanctions is not probable. Accordingly, no accrual has been made as of June 30, 2021. If the Company is found to be in contempt of the injunction, Oracle may seek equitable, punitive, and compensatory relief, the outcome of which could have a material adverse effect on the Company’s business and financial condition. Rimini II Litigation In October 2014, the Company filed a separate lawsuit, Rimini Street Inc. v. Oracle Int’l Corp. , in the District Court against Oracle seeking a declaratory judgment that the Company’s revised “Process 2.0” support practices, in use since at least July 2014, do not infringe certain Oracle copyrights (“Rimini II”). The Company’s operative complaint asserts declaratory judgment, tort, and statutory claims. Oracle’s operative counterclaim asserts declaratory judgment and copyright infringement claims and Lanham Act, breach of contract, and business tort violations. On September 15, 2020, the District Court issued an order resolving the parties’ motions for summary judgment. It found infringement of 17 Oracle PeopleSoft copyrights for work the Company performed for a set of “gap customers” that were supported by processes litigated in Rimini I, and that became the Company’s customers after Rimini I was filed. The District Court also found infringement of four Oracle PeopleSoft copyrights involving support of two specific Company clients, described by the District Court as “limited cases” and involving “limited circumstance[s].” There was no finding of infringement on any other Oracle copyrights at issue. The order also resolved several of the non-copyright claims asserted by the parties: (i) allowing the Company’s claim for injunctive relief against Oracle for unfair competition in violation of the California Business & Professions Code §17200 et seq. to proceed to trial; (ii) granting summary judgment for Oracle on the Company’s affirmative claims for damages under the Nevada and California unfair and deceptive trade practices statutes; and (iii) holding that Oracle had the right to revoke the Company’s access to its websites. The Court also reiterated that the Company has the legal right to provide aftermarket support for Oracle’s enterprise software. The parties filed their joint pretrial order in Rimini II in December 2020. Also in December 2020, Oracle filed a motion to realign the parties and bifurcate trial, asking the District Court to (i) realign the parties, with Oracle designated as plaintiff and the Company and Mr. Ravin designated as the defendants in the case caption and at trial, and (ii) bifurcate the trial with a jury trial phase proceeding, first, followed by a separate bench phase on the parties’ equitable claims for unfair competition and Oracle’s claim for an accounting. In January 2021, the Company filed a motion to modify the order of proof and for an advisory jury verdict, asking the District Court to (i) modify the order of proof in the case so that, at trial, Oracle will present its case-in-chief first, followed by the Company’s case-in-chief, (ii) not bifurcate the parties’ unfair competition claims or Oracle’s accounting claim from the other claims, (iii) empanel an advisory jury to make findings of fact with respect to the parties’ unfair competition claims and Oracle’s accounting claim, and (iv) hold a single jury trial. As of this date, no damages of any kind have been awarded by the District Court in Rimini II. Damages, if any, will be a decision for the Rimini II jury. The Company reserves all rights, including appellate rights, with respect to the District Court and jury rulings and findings in Rimini II. There is currently no trial date scheduled, and while the Company does not expect a trial to occur in this matter earlier than the first half of 2022, the trial could occur earlier or later than that. At this time, the Company does not have sufficient information regarding possible damages exposure for the counterclaims asserted by Oracle. As to the claims asserted by Oracle, in Rimini I, the jury awarded damages in the form of a fair market value license of $35.4 million for the 93 copyrighted works at issue, which the Company has paid. The parties dispute the relevance of that award for Rimini II, and the Court has not yet resolved that dispute. The Company maintains that zero damages should be awarded in Rimini II. A jury will ultimately determine what amount, if any, of damages to award. Both parties have sought injunctive relief in addition to monetary damages in this matter, and the Company has reserved its rights to appeal regarding the possible recovery of damages by the Company in connection with the Company’s claims against Oracle. As a result, an estimate of the range of loss cannot be reasonably determined. The Company also believes that an award for damages payable to Oracle is not probable, so no accrual has been made as of June 30, 2021. However, as with any jury trial, the ultimate outcome may be different from our best estimates and could have a material adverse impact on our financial results and our business. Other Litigation From time to time, the Company may be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these ordinary course matters will not have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of judgment, defense and settlement costs, diversion of management resources and other factors. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies . Legal fees are expensed as incurred. Liquidated Damages The Company enters into agreements with clients that contain provisions related to liquidated damages that would be triggered in the event that the Company is no longer able to provide services to these clients. The maximum cash payments related to these liquidated damages is approximately $12.8 million and $13.8 million as of June 30, 2021 and December 31, 2020, respectively. To date, the Company has not incurred any costs as a result of such provisions and has not accrued any liabilities related to such provisions in these unaudited condensed consolidated financial statements.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Rimini Street, Inc. (“RSI”) was incorporated in the state of Nevada in September 2005. RSI provides enterprise software support services. In May 2017, RSI entered into an Agreement and Plan of Merger (the “Merger Agreement”) with GP Investments Acquisition Corp. (“GPIA”), a publicly-held special purpose acquisition company (“SPAC”) incorporated in the Cayman Islands and formed for the purpose of effecting a business combination with one or more businesses. The Merger Agreement was approved by the respective shareholders of RSI and GPIA in October 2017, and closing occurred on October 10, 2017, resulting in (i) the merger of a wholly-owned subsidiary of GPIA with and into RSI, with RSI as the surviving corporation, after which (ii) RSI merged with and into GPIA, with GPIA as the surviving corporation and renamed “Rimini Street, Inc.” (referred to herein as “RMNI”, as distinguished from RSI, which is defined as the predecessor entity with the same legal name) immediately after consummation of the second merger. Prior to the consummation of the mergers, the ultimate parent entity of GPIA was GP Investments, Ltd. (“GP Investments”), a global private equity firm and an affiliate of the Company. An affiliate of GP Investments (Mr. Antonio Bonchristiano) was a member of our Board of Directors until May 5, 2020.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE The Company computes earnings per share in accordance with ASC Topic 260, Earnings per Share , which requires earnings per share for each class of stock to be calculated using the two-class method. The holders of Series A Preferred Stock are entitled to participate in Common Stock dividends, if and when declared, on a one-to-one per-share basis. Accordingly, in periods in which the Company has net income, earnings per share will be computed using the two-class method whereby the pro rata dividends on Common Stock that are also distributable to the holders of Series A Preferred Stock will be deducted from earnings applicable to common stockholders, regardless of whether a dividend is declared for such undistributed earnings. Under the two-class method, earnings for the reporting period are allocated between the holders of the Company’s Common Stock and the Series A Preferred Stock based on their respective participation rights in undistributed earnings. Basic earnings per share of Common Stock is computed by dividing net income attributable to common stockholders by the weighted average number of shares of basic Common Stock outstanding. Net income allocated to the holders of the Company’s Series A Preferred Stock is calculated based on the shareholders’ proportionate share of the weighted average shares of Common Stock outstanding on an if-converted basis. Diluted earnings per share of Common Stock is calculated by adjusting the basic earnings per share of Common Stock for the effects of potential dilutive Common Stock shares outstanding such as stock options, restricted stock units and warrants. For the three months ended June 30, 2021 and 2020, basic and diluted net earnings per share of Common Stock were computed by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding during the respective periods. The following tables set forth the computation of basic and diluted net loss attributable to common stockholders for the three months ended June 30, 2021 and 2020 (in thousands, except per share amounts): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Income attributable to common stockholders: Net income $ 6,807 $ 2,924 $ 3,231 $ 5,469 Return on repurchase of Series A Preferred Stock shares — — (38) — Accretion related to redemption of Series A Preferred Stock (5,673) — (5,673) — Make-whole dividends related to redemption of Series A Preferred Stock (2,343) — (2,343) — Dividends and accretion related to Series A Preferred Stock: Cash dividends declared (2,179) (3,939) (5,839) (7,849) PIK dividends declared (654) (1,181) (1,752) (2,354) Accretion of discount (804) (1,567) (2,277) (3,114) (4,846) (3,763) (14,691) (7,848) Undistributed earnings allocated using the two-class method — — — — Net loss attributable to common stockholders $ (4,846) $ (3,763) $ (14,691) $ (7,848) Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Weighted average number of shares of Common Stock outstanding 85,343 68,290 82,056 68,076 Additional shares outstanding if Series A Preferred Stock is converted to Common Stock 9,770 15,755 12,197 15,697 Total shares outstanding if Series A Preferred Stock is converted to Common Stock 95,113 84,045 94,253 83,773 Percentage of shares allocable to Series A Preferred Stock 10.3 % 18.7 % 12.9 % 18.7 % Weighted average number of shares of Common Stock outstanding: Basic and diluted 85,343 68,290 82,056 68,076 Net loss per share attributable to common stockholders: Basic and diluted $ (0.06) $ (0.06) $ (0.18) $ (0.12) For both the three months and six months ended June 30, 2021 and 2020, basic and diluted loss per share attributable to common stockholders were the same because all Common Stock equivalents were anti-dilutive. If the Company had recorded net income attributable to common stockholders, the diluted shares would have been as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Restricted stock units 1,740 486 1,738 443 Stock options 1,682 1,696 1,862 1,836 Warrants 786 — 860 — Total 4,208 2,182 4,460 2,279 As of June 30, 2021 and December 31, 2020, the following potential Common Stock equivalents were excluded from the computation of diluted net loss per share for the respective periods ending on these dates since the impact of inclusion was anti-dilutive (in thousands): 2021 2020 Series A Preferred Stock 8,716 15,491 Restricted stock units 3,556 3,322 Stock options 6,711 7,007 Warrants 18,128 18,128 Total 37,111 43,948

FINANCIAL INSTRUMENTS AND SIGNI

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS	6 Months Ended
	Jun. 30, 2021
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS	FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Fair Value Measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts, and considers assumptions that market participants would use when pricing the asset or liability. Additional information on fair value measurements is included in Note 13 to the Company’s consolidated financial statements for the year ended December 31, 2020, included in the 2020 Form 10-K/A. The Company’s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. As of June 30, 2021 and December 31, 2020, the Company has determined that its GP Sponsor Private Placement Warrants are subject to treatment as a liability. The GP Sponsor Private Placement Warrants may not be redeemed by the Company so long as these warrants are held by the initial purchasers or such purchasers’ permitted transferees. If these warrants are held by someone other than the initial purchasers or such purchasers’ permitted transferees, these warrants are redeemable by the Company and exercisable on the same basis as certain warrants to purchase approximately 8.6 million shares of the Company’s Common Stock, at $11.50 per share (the “Public Warrants”). As a result, the GP Sponsor Private Placement Warrants were reclassified as a liability. The fair value of these instruments as of June 30, 2021 and December 31, 2020 was $3.1 million and $2.1 million, respectively, utilizing the BSM method. The GP Sponsor Private Placement Warrants are classified as Level 2 financial instruments. The key assumptions used to determine the fair value was the term period of the warrants, the risk free rate and volatility. As of June 30, 2021, the term to expiration was 1.28 years, the risk free rate of 0.12% and the implied volatility of 58.8%. As discussed in Note 5, the fair value for the Company’s Series A Preferred Stock issuances on June 20, 2019, March 7, 2019 and July 19, 2018 was determined to be $3.0 million, $5.3 million and $126.8 million, respectively, which were utilized to determine the basis for allocating the net proceeds. The fair value was determined by utilizing a combination of a discounted cash flow methodology related to funds generated by the Series A Preferred Stock, along with the BSM option-pricing model in relation to the conversion feature. Key assumptions applied for the discounted cash flow and BSM analysis included (i) three different scenarios whereby the Series A Preferred Stock would remain outstanding between 4 and 5 years along with a probability weighting assigned to each scenario, (ii) an implied yield of the Series A Preferred Stock ranging from 20.9% to 22.9% calibrated to the transaction values as of June 20, 2019, March 7, 2019 and July 19, 2018, respectively, (iii) risk-free interest rates of 1.72%, 2.44% and 2.8% and (iv) historical volatility of 30.0%. The carrying amounts of the Company’s financial instruments including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate fair values due to their short-term maturities. Based on borrowing rates currently available to the Company for debt with similar terms, the carrying value of capital lease obligations approximate fair value as of the respective balance sheet dates. The liability for redeemable warrants are also considered financial instruments and valued utilizing the BSM method and assumptions noted above. Significant Concentrations The Company attributes revenues to geographic regions based on the location of its clients’ contracting entity. The following table shows revenues by geographic region (in thousands): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 United States of America $ 49,562 $ 47,376 $ 97,121 $ 94,822 International 42,052 31,026 82,388 61,612 Total $ 91,614 $ 78,402 $ 179,509 $ 156,434 No clients represented more than 10% of revenue for both the three months and six months ended June 30, 2021 or 2020. As of June 30, 2021 and 2020, no clients accounted for more than 10% of total net accounts receivable. The Company tracks its assets by physical location. As of June 30, 2021 and 2020, the net carrying value of the Company’s property and equipment located outside of the United States amounted to approximately $1.2 million and $1.3 million, respectively. As of June 30, 2021, the Company had operating lease right-of-use assets of $10.1 million, $5.2 million and $0.4 million in the United States, India and the rest of the world, respectively. Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and accounts receivable. The Company maintains its cash, cash equivalents and restricted cash at high-quality financial institutions, primarily in the United States. Deposits, including those held in foreign branches of global banks, may exceed the amount of insurance provided on such deposits. As of June 30, 2021 and December 31, 2020, the Company had cash, cash equivalents and restricted cash with a single financial institution for an aggregate of $84.6 million and $50.2 million, respectively. As of June 30, 2021 and December 31, 2020, the Company had restricted cash of $0.3 million and $0.3 million, respectively. The Company has never experienced any losses related to these balances. Generally, credit risk with respect to accounts receivable is diversified due to the number of entities comprising the Company’s client base and their dispersion across different geographies and industries. The Company performs ongoing credit evaluations on certain clients and generally does not require collateral on accounts receivable. The Company maintains reserves for potential bad debts and historically such losses are generally not significant.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
LEASES	LEASES Effective at the start of fiscal 2020, the Company adopted the provisions and expanded disclosure requirements described in Accounting Standards Codification (ASC) Topic 842, Lease s. The Company adopted the standard using the prospective method. The Company has operating leases for real estate and equipment with an option to renew the leases for up to one month to five years. Some of the leases include the option to terminate the leases upon 30-days notice with a penalty. The Company’s leases have various remaining lease terms ranging from July 2021 to January 2027. The Company’s lease agreements may include renewal or termination options for varying periods that are generally at the Company's discretion. The Company’s lease terms only include those periods related to renewal options the Company believes are reasonably certain to exercise. The Company generally does not include these renewal options as it is not reasonably certain to renew at the lease commencement date. This determination is based on consideration of certain economic, strategic and other factors that the Company evaluates at lease commencement date and reevaluates throughout the lease term. Some leases also include options to terminate the leases and the Company only includes those periods beyond the termination date if it is reasonably certain not to exercise the termination option. The Company uses a discount rate to calculate the right of use (“ROU”) asset and lease liability. When the implicit rate is known or provided in the lease documents, the Company is required to use this rate. In cases in which the implicit rate is not known, the Company uses an estimated incremental borrowing rate. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance and tax payments. The variable portion of lease payments is not included in the Company’s ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred and are included in lease expenses recorded in selling and administrative expenses on the Consolidated Statements of Operations and Comprehensive Income. The Company has lease agreements with both lease and non-lease components that are treated as a single lease component for all underlying asset classes. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses. The Company has elected to apply the short-term lease exception for all underlying asset classes. That is, leases with a term of 12 months or less are not recognized on the balance sheet, but rather expensed on a straight-line basis over the lease term. The Company’s leases do not include significant restrictions or covenants, and residual value guarantees are generally not included within its operating leases. As of June 30, 2021, the Company did not have any material additional operating leases that have not yet commenced. The components of lease expense and supplemental balance sheet information were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease expense related to ROU assets and liabilities $ 1,546 $ 1,548 $ 3,100 $ 3,047 Other lease expense 132 297 292 615 Total lease expense $ 1,678 $ 1,845 $ 3,392 $ 3,662 Other information related to leases was as follows (in thousands): Supplemental Balance Sheet Information June 30, 2021 December 31, 2020 Operating lease right-of-use assets, noncurrent $ 15,772 $ 17,521 June 30, 2021 December 31, 2020 Operating lease liabilities, current $ 4,055 $ 3,940 Operating lease liabilities, noncurrent 14,495 15,993 Total operating lease liabilities $ 18,550 $ 19,933 Weighted Average Remaining Lease Term Years Operating leases 4.41 Weighted Average Discount Rate Operating leases 10.5 % Maturities of operating lease liabilities as of June 30, 2021 were as follows (in thousands): Year ending June 30: 2022 $ 5,774 2023 5,198 2024 4,489 2025 4,002 2026 2,402 Thereafter 1,443 Total future undiscounted lease payments 23,308 Less imputed interest (4,758) Total $ 18,550

LIQUIDITY AND SIGNIFICANT ACC_2

LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Nature of Business	Nature of Business
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). All significant intercompany balances and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, certain information and footnote disclosures required by U.S. GAAP for complete financial statements have been condensed or omitted in accordance with such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2020, included in the Company’s 2020 Annual Report on Form 10-K as filed with the SEC on March 3, 2021 and as subsequently amended on May 10, 2021 (as amended, the “2020 Form 10-K/A”). The accompanying condensed consolidated balance sheet and related disclosures as of December 31, 2020 have been derived from the Company’s audited financial statements. The Company’s financial condition as of June 30, 2021, and operating results for the three months ended June 30, 2021, are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the year ending December 31, 2021.
Use of Estimates	Use of Estimates The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, accounts receivable, valuation assumptions for stock options and leases, deferred income taxes and the related valuation allowances, and the evaluation and measurement of contingencies. To the extent there are material differences between the Company’s estimates and actual results, the Company’s future consolidated results of operation may be affected.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Standards. The following accounting standards were adopted during the fiscal year 2021: In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . The guidance removes certain exceptions to the general income tax accounting principles, and clarifies and amends existing guidance to facilitate consistent application of the accounting principles. The new guidance was effective for the Company as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s Consolidated Financial Statements. In January 2020, the FASB issued ASU 2020-1 , Investments—Equity Securities (Topic 321), Investments - Equity and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) . The guidance clarifies interactions between current accounting standards on equity securities, equity method and joint ventures, and derivatives and hedging. The new guidance addresses accounting for the transition into and out of the equity method and measuring certain purchased options and forward contracts to acquire investments. The new guidance was effective for the Company as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s Consolidated Financial Statements.
Earnings Per Share	The Company computes earnings per share in accordance with ASC Topic 260, Earnings per Share , which requires earnings per share for each class of stock to be calculated using the two-class method. The holders of Series A Preferred Stock are entitled to participate in Common Stock dividends, if and when declared, on a one-to-one per-share basis. Accordingly, in periods in which the Company has net income, earnings per share will be computed using the two-class method whereby the pro rata dividends on Common Stock that are also distributable to the holders of Series A Preferred Stock will be deducted from earnings applicable to common stockholders, regardless of whether a dividend is declared for such undistributed earnings. Under the two-class method, earnings for the reporting period are allocated between the holders of the Company’s Common Stock and the Series A Preferred Stock based on their respective participation rights in undistributed earnings. Basic earnings per share of Common Stock is computed by dividing net income attributable to common stockholders by the weighted average number of shares of basic Common Stock outstanding. Net income allocated to the holders of the Company’s Series A Preferred Stock is calculated based on the shareholders’ proportionate share of the weighted average shares of Common Stock outstanding on an if-converted basis. Diluted earnings per share of Common Stock is calculated by adjusting

DEFERRED CONTRACT COSTS AND D_2

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Contract Liabilities	Activity for deferred contract costs for the three and six months ended June 30, 2021 and 2020 is shown below (in thousands): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Deferred contract costs, current and noncurrent, as of the beginning of period $ 34,500 $ 28,472 $ 34,945 $ 28,049 Capitalized commissions during the period 5,868 4,289 9,142 8,042 Amortized deferred contract costs during the period (3,807) (3,377) (7,526) (6,707) Deferred contract costs, current and noncurrent, as of the end of period $ 36,561 $ 29,384 $ 36,561 $ 29,384 Deferred revenue activity for the three and six months ended June 30, 2021 and 2020 is shown below (in thousands): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Deferred revenue, current and noncurrent, as of the beginning of period $ 249,997 $ 222,654 $ 256,933 $ 235,498 Billings, net 107,255 74,254 188,214 139,442 Revenue recognized (91,614) (78,402) (179,509) (156,434) Deferred revenue, current and noncurrent, as of the end of period $ 265,638 $ 218,506 $ 265,638 $ 218,506

OTHER FINANCIAL INFORMATION (Ta

OTHER FINANCIAL INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Other Accrued Liabilities	As of June 30, 2021 and December 31, 2020, other accrued liabilities consist of the following (in thousands): 2021 2020 Accrued sales and other taxes $ 4,288 $ 5,213 Accrued professional fees 4,908 5,912 Accrued dividends on Redeemable Series A Preferred Stock 2,186 3,842 Current maturities of capital lease obligations 369 429 Income taxes payable 1,038 2,245 Other accrued expenses 3,137 3,513 Total other accrued liabilities $ 15,926 $ 21,154

REDEEMABLE SERIES A PREFERRED_2

REDEEMABLE SERIES A PREFERRED STOCK (Tables)	6 Months Ended
	Jun. 30, 2021
Temporary Equity Disclosure [Abstract]
Allocation Private Placement Proceeds	The allocation of the net proceeds as of the closing date, along with changes in the net carrying value of the Series A Preferred Stock through June 30, 2021, are set forth below (dollars in thousands): Series A Preferred Stock Common Convertible Shares Amount Stock Notes Total Fair value on July 19, 2018: Series A Preferred Stock 140,000 $ 126,763 (1) $ — $ — $ 126,763 Common Stock — — 20,131 (2) — 20,131 Convertible Notes — — — — — Total 140,000 $ 126,763 $ 20,131 $ — $ 146,894 Relative fair value allocation on July 19, 2018 Aggregate cash proceeds on July 19, 2018 140,000 $ 114,773 (3) $ 18,227 (3) $ — $ 133,000 Incremental and direct costs — (3,994) (4) (634) (4) — (4,628) Net carrying value on July 19, 2018 140,000 $ 110,779 $ 17,593 $ — $ 128,372 _________________ (1) The liquidation preference for each share of Series A Preferred Stock on the closing date for the Initial Private Placement was $1,000 per share for an aggregate liquidation preference of $140.0 million. The estimated fair value of the Series A Preferred Stock was approximately $126.8 million on July 19, 2018, which is the basis for allocation of the net proceeds. Please refer to Note 11 for further discussion of the valuation methodology employed. (2) The fair value of the issuance of approximately 2.9 million shares of Common Stock was based on the last closing price of $6.95 per share on the date prior to closing the transaction. (3) The aggregate cash proceeds of $133.0 million on July 19, 2018 were allocated pro rata based on the fair value of all consideration issued. (4) Incremental and direct costs of the Initial Private Placement were allocated pro rata based on the fair value of all consideration issued. Such costs include financial advisory and professional fees of $2.7 million that were incurred by the Company, and due diligence and professional fees incurred by the investors of $1.9 million. Series A Preferred Stock Common Convertible Shares Amount Stock Notes Total Fair value on March 7, 2019: Series A Preferred Stock 6,500 $ 5,313 (1) $ — $ — $ 5,313 Common Stock — — 722 (2) — 722 Convertible Notes — — — — — Total 6,500 $ 5,313 $ 722 $ — $ 6,035 Relative fair value allocation on March 7, 2019: Aggregate cash proceeds on March 7, 2019 6,500 $ 5,093 (3) $ 692 (3) $ — $ 5,785 Incremental and direct costs — (661) (4) (90) (4) — (751) Net carrying value on March 7, 2019 6,500 $ 4,432 $ 602 $ — $ 5,034 (1) The liquidation preference for each share of Series A Preferred Stock on the closing date for the March 2019 Private Placement was $1,000 per share for an aggregate liquidation preference of $6.5 million. The estimated fair value of the Series A Preferred Stock was approximately $5.3 million on March 7, 2019, which is the basis for allocation of the net proceeds. Please refer to Note 11 for further discussion of the valuation methodology employed. (2) The fair value of the issuance of approximately 134,483 shares of Common Stock was based on the closing price of $5.37 per share on the date prior to closing of the transaction. (3) The aggregate cash proceeds of $5.8 million on March 7, 2019 were allocated pro rata based on the fair value of all consideration issued. (4) Incremental and direct costs related to the March 2019 Private Placement were allocated pro rata based on the fair value of all consideration issued. Such costs included the issuance of 85,000 shares of Common Stock to the Initial Private Placement investors in the Series A Preferred Stock for their consent of approximately $0.5 million and financial advisory and professional fees that were incurred of approximately $0.3 million that were either paid or accrued directly by the Company as of March 31, 2019. The allocation of the net proceeds from the June 2019 Private Placement are set forth below (dollars in thousands): Series A Preferred Stock Common Convertible Shares Amount Stock Notes Total Fair value on June 20, 2019: Series A Preferred Stock 3,500 $ 2,997 (1) $ — $ — $ 2,997 Common Stock — — 376 (2) — 376 Convertible Notes — — — — — Total 3,500 $ 2,997 $ 376 $ — $ 3,373 Relative fair value allocation on June 20, 2019: Aggregate cash proceeds on June 20, 2019 3,500 $ 2,954 (3) $ 371 (3) $ — $ 3,325 Incremental and direct costs — (301) (4) (38) (4) — (339) Net carrying value on June 20, 2019 3,500 $ 2,653 $ 333 $ — $ 2,986 (1) The liquidation preference for each share of Series A Preferred Stock on the closing date for the June 2019 Private Placement was $1,000 per share for an aggregate liquidation preference of $3.5 million. The estimated fair value of the Series A Preferred Stock was approximately $3.0 million on June 20, 2019, which is the basis for allocation of the net proceeds. Please refer to Note 11 for further discussion of the valuation methodology employed. (2) The fair value of the issuance of approximately 72,414 shares of Common Stock was based on the closing price of $5.19 per share on the date prior to closing of the transaction. (3) The aggregate cash proceeds of $3.3 million on June 20, 2019 were allocated pro rata based on the fair value of all consideration issued. (4) Incremental and direct costs related to the June 2019 Private Placement were allocated pro rata based on the fair value of all consideration issued. Such costs included the issuance of 35,000 shares of Common Stock to the Initial Private Placement investors in the Series A Preferred Stock for their consent of approximately $0.2 million and financial advisory and professional fees that were incurred of approximately $0.2 million that were either paid or accrued directly by the Company as of June 30, 2019.
Temporary Equity	The changes in the net carrying value of Series A Preferred Stock from December 31, 2020 to June 30, 2021 are set forth below (dollars in thousands): Series A Preferred Stock Shares Amount Net carrying value as of December 31, 2020 154,911 $ 137,854 Issuance of shares to settle PIK Dividends on January 4, 2021 1,193 1,193 Repurchase of 10,000 shares on January 5, 2021 (10,000) (8,913) Accretion of discount for the three months ended March 31, 2021 — 1,473 Net carrying value as of March 31, 2021 146,104 131,607 Issuance of shares to settled PIK Dividends on April 1, 2021 1,051 1,051 Redemption of 60,000 shares on April 16, 2021 (60,000) (54,327) Accretion of discount for the three months ended June 30, 2021 — 804 Net carrying value as of June 30, 2021 87,155 $ 79,135
Dividends Declared	Presented below is a summary of total and per share dividends declared through June 30, 2021 (dollars in thousands, except per share amounts): Dividends Payable in: Total Dividends Cash PIK Dividends Per Share Dividends payable as of December 31, 2020 $ 3,842 $ 1,193 $ 5,035 $ 32.50 Cash Dividends 10% per annum 3,660 — 3,660 23.40 PIK Dividends 3% per annum — 1,098 1,098 7.02 Fractional PIK shares settled for cash 47 (47) — — Less dividends settled January 4, 2021 (4,009) (1,193) (5,202) (33.26) Dividends payable as of March 31, 2021 3,540 1,051 4,591 32.14 Cash Dividends 10% per annum 2,179 — 2,179 25.00 PIK Dividends 3% per annum — 654 654 7.50 Fractional PIK shares settled for cash 7 (7) — — Less dividends settled April 1, 2021 (3,540) (1,051) (4,591) (52.68) Dividends payable as of June 30, 2021 $ 2,186 $ 647 $ 2,833 $ 32.51

COMMON STOCK OFFERING, RESTRI_2

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The following table sets forth a summary of stock option activity under the Stock Plans for the six months ended June 30, 2021 (shares in thousands): Shares Price (1) Term (2) Outstanding, December 31, 2020 7,007 $ 5.24 5.0 Granted 665 7.61 Forfeited (65) 4.74 Expired (95) 6.45 Exercised (801) 3.87 Outstanding, June 30, 2021 (3)(4) 6,711 5.62 5.2 Vested, June 30, 2021 (3) 5,386 5.50 4.3 (1) Represents the weighted average exercise price. (2) Represents the weighted average remaining contractual term until the stock options expire. (3) As of June 30, 2021, the aggregate intrinsic value of all stock options outstanding was $8.2 million. As of June 30, 2021, the aggregate intrinsic value of vested stock options was $7.1 million. (4) The number of outstanding stock options that are not expected to ultimately vest due to forfeiture amounted to 0.2 million shares as of June 30, 2021.
Schedule of Shares Available for Grant Activity	The following table presents activity affecting the total number of shares available for grant under the Stock Plans for the six months ended June 30, 2021 (in thousands): Available, December 31, 2020 4,037 Newly authorized by Board of Directors 3,056 Stock options granted (665) Restricted stock units granted (1,085) Expired options under Stock Plans 95 Forfeited options under Stock Plans 65 Forfeited restricted stock units under Stock Plans 105 Available, June 30, 2021 5,608
Schedule of Assumptions of Fair Value of Stock Option Grants	For the six months ended June 30, 2021, the fair value of each stock option grant under the Stock Plans was estimated on the date of grant using the BSM option-pricing model, with the following weighted-average assumptions: Expected life (in years) 6.0 Volatility 41% Dividend yield 0% Risk-free interest rate 0.86% Fair value per common share on date of grant $7.61
Schedule of Stock-based Compensation Expense	Stock-based compensation expense attributable to RSUs and stock options is classified as follows (in thousands): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Cost of revenues $ 375 $ 279 $ 691 $ 563 Sales and marketing 874 637 1,601 1,260 General and administrative 1,229 810 2,419 1,413 Total $ 2,478 $ 1,726 $ 4,711 $ 3,236

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following tables set forth the computation of basic and diluted net loss attributable to common stockholders for the three months ended June 30, 2021 and 2020 (in thousands, except per share amounts): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Income attributable to common stockholders: Net income $ 6,807 $ 2,924 $ 3,231 $ 5,469 Return on repurchase of Series A Preferred Stock shares — — (38) — Accretion related to redemption of Series A Preferred Stock (5,673) — (5,673) — Make-whole dividends related to redemption of Series A Preferred Stock (2,343) — (2,343) — Dividends and accretion related to Series A Preferred Stock: Cash dividends declared (2,179) (3,939) (5,839) (7,849) PIK dividends declared (654) (1,181) (1,752) (2,354) Accretion of discount (804) (1,567) (2,277) (3,114) (4,846) (3,763) (14,691) (7,848) Undistributed earnings allocated using the two-class method — — — — Net loss attributable to common stockholders $ (4,846) $ (3,763) $ (14,691) $ (7,848) Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 Weighted average number of shares of Common Stock outstanding 85,343 68,290 82,056 68,076 Additional shares outstanding if Series A Preferred Stock is converted to Common Stock 9,770 15,755 12,197 15,697 Total shares outstanding if Series A Preferred Stock is converted to Common Stock 95,113 84,045 94,253 83,773 Percentage of shares allocable to Series A Preferred Stock 10.3 % 18.7 % 12.9 % 18.7 % Weighted average number of shares of Common Stock outstanding: Basic and diluted 85,343 68,290 82,056 68,076 Net loss per share attributable to common stockholders: Basic and diluted $ (0.06) $ (0.06) $ (0.18) $ (0.12)
Schedule of Weighted Average Number of Shares	If the Company had recorded net income attributable to common stockholders, the diluted shares would have been as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Restricted stock units 1,740 486 1,738 443 Stock options 1,682 1,696 1,862 1,836 Warrants 786 — 860 — Total 4,208 2,182 4,460 2,279
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	As of June 30, 2021 and December 31, 2020, the following potential Common Stock equivalents were excluded from the computation of diluted net loss per share for the respective periods ending on these dates since the impact of inclusion was anti-dilutive (in thousands): 2021 2020 Series A Preferred Stock 8,716 15,491 Restricted stock units 3,556 3,322 Stock options 6,711 7,007 Warrants 18,128 18,128 Total 37,111 43,948

FINANCIAL INSTRUMENTS AND SIG_2

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)	6 Months Ended
	Jun. 30, 2021
Investments, All Other Investments [Abstract]
Schedule of Revenues by Geographic Regions	The Company attributes revenues to geographic regions based on the location of its clients’ contracting entity. The following table shows revenues by geographic region (in thousands): Three Months Ended Six Months Ended June 30, 2021 2020 2021 2020 United States of America $ 49,562 $ 47,376 $ 97,121 $ 94,822 International 42,052 31,026 82,388 61,612 Total $ 91,614 $ 78,402 $ 179,509 $ 156,434

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Components of Lease Expense	The components of lease expense and supplemental balance sheet information were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Operating lease expense related to ROU assets and liabilities $ 1,546 $ 1,548 $ 3,100 $ 3,047 Other lease expense 132 297 292 615 Total lease expense $ 1,678 $ 1,845 $ 3,392 $ 3,662 Other information related to leases was as follows (in thousands): Supplemental Balance Sheet Information June 30, 2021 December 31, 2020 Operating lease right-of-use assets, noncurrent $ 15,772 $ 17,521 June 30, 2021 December 31, 2020 Operating lease liabilities, current $ 4,055 $ 3,940 Operating lease liabilities, noncurrent 14,495 15,993 Total operating lease liabilities $ 18,550 $ 19,933 Weighted Average Remaining Lease Term Years Operating leases 4.41 Weighted Average Discount Rate Operating leases 10.5 %
Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of June 30, 2021 were as follows (in thousands): Year ending June 30: 2022 $ 5,774 2023 5,198 2024 4,489 2025 4,002 2026 2,402 Thereafter 1,443 Total future undiscounted lease payments 23,308 Less imputed interest (4,758) Total $ 18,550

LIQUIDITY AND SIGNIFICANT ACC_3

LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 16, 2021	Mar. 11, 2021	Aug. 18, 2020	Jun. 20, 2019	Mar. 07, 2019	Jul. 19, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021	Jan. 05, 2021	Dec. 31, 2020	Oct. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Significant Accounting Policies Disclosure [Line Items]
Working capital deficit									$ 66,100
Net loss							$ 6,807	$ 2,924	3,231	$ 5,469
Cash, cash equivalents, restricted cash and restricted cash equivalents							110,721	73,005	110,721	73,005			$ 87,909			$ 38,388
Deferred revenue, current							$ 229,800		$ 229,800
Historical cost of goods and services (as a percent of deferred revenue)									38.00%
Common stock, par value (USD per share)							$ 0.0001		$ 0.0001				$ 0.0001
Underwriter discounts and commissions									$ 2,948	0
Underwriter expenses									1,050	0
Professional fees						$ 200
Operating and capital lease payments due within next twelve months							$ 6,400		6,400
Fair value instruments							3,092		3,092				$ 2,122
Other operating activities, cash flow statement								500		500
Stockholders' equity attributable to parent							$ 156,229	227,788	$ 156,229	227,788	$ 154,495		$ 203,060		$ 226,405	223,321
GP Sponsor Private Placement Warrants
Significant Accounting Policies Disclosure [Line Items]
Warrants outstanding (shares)													6,100,000
Exercise price of warrants (in USD per share)													$ 11.50
Revision of Prior Period, Adjustment
Significant Accounting Policies Disclosure [Line Items]
Stockholders' equity attributable to parent								$ (1,300)		$ (1,300)						$ (700)
Series A Preferred Stock
Significant Accounting Policies Disclosure [Line Items]
Sale of stock (shares)		60,000	60,000
Price per share (usd per share)	$ 1,000
Gross proceeds	$ 80,800
Dividend rate (as a percent)							13.00%		13.00%
Value of shares authorized to be repurchased	$ 62,300											$ 8,950		$ 4,500
August 2020 Offering
Significant Accounting Policies Disclosure [Line Items]
Sale of stock (shares)		7,800,000	6,100,000
Common stock, par value (USD per share)		$ 0.0001
Price per share (usd per share)		$ 7.75	$ 4.50
Gross proceeds		$ 57,000	$ 27,500
Underwriter discounts and commissions		2,900	1,700
Underwriter expenses		200	100
Professional fees		1,300	600
Consideration received		$ 55,700	$ 25,100
Private Placement
Significant Accounting Policies Disclosure [Line Items]
Consideration received				$ 2,986	$ 5,034	$ 128,372
Private Placement | Series A Preferred Stock
Significant Accounting Policies Disclosure [Line Items]
Sale of stock (shares)				3,500	6,500	140,000			60,000

DEFERRED CONTRACT COSTS AND D_3

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Capitalized Contract Cost, Net [Abstract]
Deferred contract costs, current and noncurrent, as of the beginning of period	$ 34,500	$ 28,472	$ 34,945	$ 28,049
Capitalized commissions during the period	5,868	4,289	9,142	8,042
Amortized deferred contract costs during the period	(3,807)	(3,377)	(7,526)	(6,707)
Deferred contract costs, current and noncurrent, as of the end of period	36,561	29,384	36,561	29,384
Change in Contract with Customer, Liability [Abstract]
Deferred revenue, current and noncurrent, as of the beginning of period	249,997	222,654	256,933	235,498
Billings, net	107,255	74,254	188,214	139,442
Revenue recognized	(91,614)	(78,402)	(179,509)	(156,434)
Deferred revenue, current and noncurrent, as of the end of period	265,638	$ 218,506	265,638	$ 218,506
Deferred revenue, current	229,768		229,768		$ 228,967
Deferred revenue, noncurrent	$ 35,870		$ 35,870		$ 27,966

OTHER FINANCIAL INFORMATION - O

OTHER FINANCIAL INFORMATION - Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued sales and other taxes	$ 4,288	$ 5,213
Accrued professional fees	4,908	5,912
Accrued dividends on Redeemable Series A Preferred Stock	2,186	3,842
Current maturities of capital lease obligations	369	429
Income taxes payable	1,038	2,245
Other accrued expenses	3,137	3,513
Total other accrued liabilities	$ 15,926	$ 21,154

OTHER FINANCIAL INFORMATION - N

OTHER FINANCIAL INFORMATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interest expense	$ 38	$ 12	$ 85	$ 25

REDEEMABLE SERIES A PREFERRED_3

REDEEMABLE SERIES A PREFERRED STOCK - Narrative (Details)	Jul. 20, 2021USD ($)$ / shares	Jul. 01, 2021shares	Jun. 18, 2021	Apr. 16, 2021USD ($)$ / sharesshares	Mar. 11, 2021shares	Aug. 18, 2020shares	Jun. 20, 2019USD ($)$ / sharesshares	Mar. 07, 2019USD ($)$ / sharesshares	Jul. 19, 2018USD ($)$ / sharesshares	Mar. 31, 2020USD ($)	Jun. 30, 2021USD ($)day$ / sharesshares	Jun. 30, 2020USD ($)	Mar. 31, 2021shares	Jan. 05, 2021USD ($)shares	Dec. 31, 2020shares	Oct. 30, 2020USD ($)shares
Securities Purchase Agreements
Discount on shares									$ 7,000,000
Line of credit unpaid transaction costs									2,700,000
Stock issuance costs											$ 1,243,000	$ 0
Professional fees									$ 200,000
Net proceeds related to issuance of Common Stock from March 2021 Offering				$ 80,700,000							$ 56,965,000	$ 0
Certificate of Designations
Redeemable preferred stock, shares authorized (shares) | shares											180,000				180,000
Number of years dividend will be effective											5 years
Dividends payable, current											$ 2,200,000
Dividends payable, non-current											$ 600,000
Temporary equity, liquidation preference (usd per share) | $ / shares									$ 1,000		$ 10
Temporary equity, shares outstanding (shares) | shares											87,155				155,000
Temporary equity, shares issued upon conversion											1
Threshold trading days | day											30
Threshold consecutive trading days											45 days
Threshold stock price, minimum (usd per share) | $ / shares											$ 11.50
Consecutive trading days prior to conversion date | day											60
Liquidation preference in case of liquidation, dissolution, or winding up of company											$ 80,000,000
Temporary equity, liquidation preference per share, in event of liquidation, dissolution, or winding up of company (usd per share) | $ / shares											$ 1,000
Outstanding percentage, indebtedness restriction (as a percent)											95.00%
Subsequent Event
Securities Purchase Agreements
Long-term debt	$ 90,000,000
Financial covenants, minimum liquidity	$ 20,000,000
Annual minimum principal payments year one	5.00%
Annual minimum principal payments year two	5.00%
Annual minimum principal payments year three	7.50%
Annual minimum principal payments year four	7.50%
Annual minimum principal payments year five	10.00%
Certificate of Designations
Series A Preferred stock issued for PIK dividends (shares) | shares		647
Subsequent Event | Minimum | LIBOR
Securities Purchase Agreements
Debt instrument, interest rate	1.75%
Subsequent Event | Maximum | LIBOR
Securities Purchase Agreements
Debt instrument, interest rate	2.50%
Funded Debt
Securities Purchase Agreements
Repayments of lines of credit									$ 132,800,000
Private Placement
Securities Purchase Agreements
Proceeds from issuance of private placement							$ 3,325,000	$ 5,785,000	133,000,000
Discount on shares							200,000	700,000
Incremental and direct transaction costs							339,000	751,000	4,628,000
Stock issuance costs							$ 300,000	$ 800,000	2,700,000
Discount on shares (as a percent)							5.00%	11.00%
Consideration received							$ 2,986,000	$ 5,034,000	$ 128,372,000
Incremental and direct costs, shares issued, cost							$ 200,000	$ 500,000
Series A Preferred Stock
Securities Purchase Agreements
Sale of stock (shares) | shares					60,000	60,000
Redemption shares issued (in shares) | shares				60,000
Redemption percentage			13.00%	13.00%
Aggregate redemption price				$ 62,300,000
Face value				$ 60,000,000
Price per share (usd per share) | $ / shares				$ 1,000
Dividends, stock				$ 2,300,000
Preferred stock, dividends per share, declared (usd per share) | $ / shares				$ 39.05
Shares authorized to be repurchased (in shares) | shares														10,000		5,000
Value of shares authorized to be repurchased				$ 62,300,000										$ 8,950,000		$ 4,500,000
Certificate of Designations
Dividend rate (as a percent)											13.00%
Series A Preferred Stock | Subsequent Event
Securities Purchase Agreements
Aggregate redemption price	$ 88,400,000
Face value	$ 87,800,000
Price per share (usd per share) | $ / shares	$ 1,000
Dividends, stock	$ 600,000
Preferred stock, dividends per share, declared (usd per share) | $ / shares	$ 6.86
Series A Preferred Stock | Private Placement
Securities Purchase Agreements
Sale of stock (shares) | shares							3,500	6,500	140,000		60,000
Proceeds from issuance of private placement							$ 2,954,000	$ 5,093,000	$ 114,773,000
Incremental and direct transaction costs							$ 301,000	$ 661,000	$ 3,994,000
Aggregate redemption price				$ 54,327,000
Shares authorized to be repurchased (in shares) | shares														10,000
Certificate of Designations
Temporary equity, liquidation preference (usd per share) | $ / shares							$ 1,000	$ 1,000
Temporary equity, shares outstanding (shares) | shares											87,155		146,104		154,911
Common Stock
Certificate of Designations
Temporary equity, shares issued upon conversion (shares) | shares											8,700,000
Common Stock
Securities Purchase Agreements
New stock issued during period (shares) | shares							72,414	134,483	2,900,000
Common Stock | Private Placement
Securities Purchase Agreements
New stock issued during period (shares) | shares							72,414	134,483
Proceeds from issuance of private placement							$ 371,000	$ 692,000	$ 18,227,000
Incremental and direct transaction costs							$ 38,000	$ 90,000	634,000
Incremental and direct costs (shares) | shares							35,000	85,000
Due Diligence And Professional Fees | Private Placement
Securities Purchase Agreements
Incremental and direct transaction costs							$ 200,000	$ 300,000	$ 1,900,000	$ 300,000
Cash Dividend
Certificate of Designations
Dividend rate (as a percent)											10.00%
Paid-In-Kind Dividend
Certificate of Designations
Dividend rate (as a percent)											3.00%

REDEEMABLE SERIES A PREFERRED_4

REDEEMABLE SERIES A PREFERRED STOCK - Series A Preferred Stock Summary (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 20, 2019	Mar. 07, 2019	Jul. 19, 2018	Mar. 31, 2020	Jun. 30, 2021	Dec. 31, 2020
Temporary Equity [Line Items]
Net carrying value					$ 79,135	$ 137,854
Common stock issued					$ 9	8
Footnotes
Temporary equity, liquidation preference (usd per share)			$ 1,000		$ 10
Redeemable preferred stock, liquidation preference	$ 3,500	$ 6,500	$ 140,000		$ 87,155	$ 154,911
Private Placement
Temporary Equity [Line Items]
Temporary stock issued	2,997	5,313	126,763
Issuance of Common Stock in March 2021 Offering, net	3,373	6,035	146,894
Aggregate cash proceeds	3,325	5,785	133,000
Incremental and direct costs	(339)	(751)	(4,628)
Consideration received	2,986	5,034	128,372
Footnotes
Temporary stock issued	2,997	5,313	126,763
Incremental and direct costs, shares issued, cost	200	500
Incremental and direct transaction costs	$ 339	$ 751	$ 4,628
Private Placement | Series A Preferred Stock
Temporary Equity [Line Items]
Temporary stock issued (shares)	3,500	6,500	140,000
Temporary stock issued	$ 2,997	$ 5,313	$ 126,763
Aggregate cash proceeds	2,954	5,093	114,773
Incremental and direct costs	(301)	(661)	(3,994)
Net carrying value	$ 2,653	$ 4,432	110,779
Footnotes
Temporary equity, liquidation preference (usd per share)	$ 1,000	$ 1,000
Temporary stock issued	$ 2,997	$ 5,313	126,763
Incremental and direct transaction costs	$ 301	$ 661	$ 3,994
Common Stock
Footnotes
New stock issued during period (shares)	72,414	134,483	2,900,000
Shares issued (usd per share)	$ 5.19	$ 5.37	$ 6.95
Common Stock | Private Placement
Temporary Equity [Line Items]
Issuance of Common Stock in March 2021 Offering, net	$ 376	$ 722	$ 20,131
Aggregate cash proceeds	371	692	18,227
Incremental and direct costs	(38)	(90)	(634)
Common stock issued	$ 333	$ 602	17,593
Footnotes
New stock issued during period (shares)	72,414	134,483
Incremental and direct costs (shares)	35,000	85,000
Incremental and direct transaction costs	$ 38	$ 90	634
Financial Advisor And Professional Fees | Private Placement
Temporary Equity [Line Items]
Incremental and direct costs			(2,700)
Footnotes
Incremental and direct transaction costs			2,700
Due Diligence And Professional Fees | Private Placement
Temporary Equity [Line Items]
Incremental and direct costs	(200)	(300)	(1,900)	$ (300)
Footnotes
Incremental and direct transaction costs	$ 200	$ 300	$ 1,900	$ 300

REDEEMABLE SERIES A PREFERRED_5

REDEEMABLE SERIES A PREFERRED STOCK - Change in Value of Temporary Equity (Details) - USD ($) $ in Thousands	Apr. 16, 2021	Apr. 01, 2021	Jan. 05, 2021	Jan. 04, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Oct. 30, 2020
Increase (Decrease) in Temporary Equity [Roll Forward]
Net carrying value beginning balance (shares)						155,000		155,000
Net carrying value beginning balance (shares)					87,155			87,155
Series A Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Shares authorized to be repurchased (in shares)			10,000							5,000
Aggregate redemption price	$ (62,300)
Accretion related to redemption of Series A Preferred Stock					$ 5,673		$ 0	$ 5,673	$ 0
Private Placement | Series A Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Net carrying value beginning balance (shares)		146,104			146,104	154,911		154,911
Net carrying value beginning balance		$ 131,607			$ 131,607	$ 137,854		$ 137,854
Issuance of shares to settle PIK Dividends (shares)		1,051		1,193
Issuance of shares to settle PIK Dividends		$ 1,051		$ 1,193
Repurchase (shares)			(10,000)
Repurchase			$ (8,913)
Shares authorized to be repurchased (in shares)			10,000
Stock redeemed or called during period (in shares)	(60,000)
Aggregate redemption price	$ (54,327)
Accretion of discount (shares)					0	0
Accretion related to redemption of Series A Preferred Stock					$ 804	$ 1,473
Net carrying value beginning balance (shares)					87,155	146,104		87,155
Net carrying value beginning balance					$ 79,135	$ 131,607		$ 79,135

REDEEMABLE SERIES A PREFERRED_6

REDEEMABLE SERIES A PREFERRED STOCK - Dividends (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 01, 2021	Jan. 04, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Dividends Payable [Roll Forward]
Cash dividends declared			$ 2,179		$ 3,939	$ 5,839	$ 7,849
Dividends, paid-in-kind			$ 654		$ 1,181	1,752	2,354
Payments of cash dividends on Series A Preferred Stock						$ (9,891)	$ (7,805)
Cash Dividend
Dividends Payable [Roll Forward]
Dividend rate (as a percent)			10.00%			10.00%
Paid-In-Kind Dividend
Dividends Payable [Roll Forward]
Dividend rate (as a percent)			3.00%			3.00%
Series A Preferred Stock
Dividends Payable [Roll Forward]
Dividends payable start of period	$ 4,591		$ 4,591	$ 5,035		$ 5,035
Dividends payable (usd per share)			$ 32.51	$ 32.14		$ 32.51		$ 32.50
Payments of cash dividends on Series A Preferred Stock	$ (4,591)	$ (5,202)
Dividends, cash paid (usd per share)	$ (52.68)	$ (33.26)
Dividends payable end of period			$ 2,833	$ 4,591		$ 2,833
Dividend rate (as a percent)			13.00%			13.00%
Series A Preferred Stock | Cash Dividend
Dividends Payable [Roll Forward]
Dividends payable start of period	$ 3,540		$ 3,540	3,842		$ 3,842
Cash dividends declared			2,179	3,660
Dividends			$ 2,179	$ 3,660
Dividends payable (usd per share)			$ 25	$ 23.40		$ 25
Payments of cash dividends on Series A Preferred Stock	(3,540)	$ (4,009)
Dividends payable end of period			$ 2,186	$ 3,540		$ 2,186
Series A Preferred Stock | Paid-In-Kind Dividend
Dividends Payable [Roll Forward]
Dividends payable start of period	1,051		1,051	1,193		$ 1,193
Cash dividends declared			7	47
Dividends, paid-in-kind			654	1,098
Dividends			$ 654	$ 1,098
Dividends payable (usd per share)			$ 7.50	$ 7.02		$ 7.50
Payments of cash dividends on Series A Preferred Stock	$ (1,051)	$ (1,193)
Dividends payable end of period			$ 647	$ 1,051		$ 647
Series A Preferred Stock | Fractional Shares
Dividends Payable [Roll Forward]
Cash dividends declared			7	47
Dividends			$ 0	$ 0
Dividends payable (usd per share)			$ 0	$ 0		$ 0

COMMON STOCK OFFERING, RESTRI_3

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 16, 2021	Mar. 11, 2021	Feb. 23, 2021	Aug. 18, 2020	Jul. 19, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Common Stock Offering
Underwriter discounts and commissions								$ 2,948	$ 0
Underwriter expenses								$ 1,050	0
Professional fees					$ 200
Stock available for grant newly authorized by Board of Directors (shares)								3,056,000
Restricted Stock Units
Stock-based compensation expense						$ 2,478	$ 1,726	$ 4,711	3,236
Stock Options
Stock options granted in period (shares)								665,000
Warrants
Warrants outstanding (shares)						18,100,000		18,100,000
Stock options
Restricted Stock Units
Period for recognition of compensation costs not yet recognized related to nonvested awards								2 years 1 month 6 days
Stock Options
Stock options granted in period (shares)								700,000
Fair value of stock options granted								$ 2,000
Weighted-average grant date fair value per share of options granted in period (usd per share)								$ 3.06
Unrecognized compensation costs						$ 2,200		$ 2,200		$ 1,200
Period for recognition of compensation costs not yet recognized related to nonvested awards								2 years 1 month 6 days
Series A Preferred Stock
Common Stock Offering
Sale of stock (shares)		60,000		60,000
Price per share (usd per share)	$ 1,000
Gross proceeds	$ 80,800
March 2021 Offering
Common Stock Offering
Sale of stock (shares)		7,800,000
Price per share (usd per share)		$ 7.75
Gross proceeds		$ 56,900
Underwriter discounts and commissions		2,900
Underwriter expenses		200
Professional fees		1,300
Consideration received		$ 55,600
August 2020 Offering
Common Stock Offering
Sale of stock (shares)		7,800,000		6,100,000
Price per share (usd per share)		$ 7.75		$ 4.50
Gross proceeds		$ 57,000		$ 27,500
Underwriter discounts and commissions		2,900		1,700
Underwriter expenses		200		100
Professional fees		1,300		600
Consideration received		$ 55,700		$ 25,100
Exercise Price $5.64
Warrants
Warrants outstanding (shares)						3,400,000		3,400,000
Exercise price of warrants (in USD per share)						$ 5.64		$ 5.64
Exercise Price $11.50
Warrants
Warrants outstanding (shares)						14,700,000		14,700,000
Exercise price of warrants (in USD per share)						$ 11.50		$ 11.50
2013 Plan
Common Stock Offering
Stock available for grant newly authorized by Board of Directors (shares)			3,100,000
2013 Plan | Stock options
Stock Options
Award vesting rights (percentage)								33.33%
2013 Plan | Restricted stock units
Restricted Stock Units
Restricted stock units granted in period (shares)						1,100,000		1,100,000
Share price of common stock on date of grant of RSUs (USD per share)								$ 7.35
Aggregate fair value of shares underlying RSU's								$ 8,000
Stock-based compensation expense						$ 2,200	$ 1,300	4,100	$ 2,500
Compensation costs not yet recognized of nonvested awards						$ 13,200		$ 13,200
Period for recognition of compensation costs not yet recognized related to nonvested awards								1 year 9 months 18 days
Stock Options
Period for recognition of compensation costs not yet recognized related to nonvested awards								1 year 9 months 18 days
2013 Plan | Minimum | Restricted stock units
Restricted Stock Units
Award vesting period								12 months
2013 Plan | Maximum | Restricted stock units
Restricted Stock Units
Award vesting period								36 months
Stock Plans | Stock options
Stock Options
Term of vested options (years)								10 years

COMMON STOCK OFFERING, RESTRI_4

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares
Shares
Outstanding at beginning of period (shares)	7,007
Granted (shares)	665
Forfeited (shares)	(65)
Expired (shares)	(95)
Exercised (shares)	(801)
Outstanding at end of period (shares)	6,711	7,007
Vested at end of period (shares)	5,386
Price
Outstanding at beginning of period (USD per share) | $ / shares	$ 5.24
Granted (USD per share) | $ / shares	7.61
Forfeited (USD per share) | $ / shares	4.74
Expired (USD per share) | $ / shares	6.45
Exercised (USD per share) | $ / shares	3.87
Outstanding at end of period (USD per share) | $ / shares	5.62	$ 5.24
Vested (USD per share) | $ / shares	$ 5.50
Term
Term of outstanding options	5 years 2 months 12 days	5 years
Term of vested options (years)	4 years 3 months 18 days
Aggregate intrinsic value of stock options outstanding | $	$ 8.2
Aggregate intrinsic value of vested stock options | $	$ 7.1
Outstanding stock options not expected to vest due to forfeitures (shares)	200

COMMON STOCK OFFERING, RESTRI_5

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Shares Available for Grant (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2021shares
Shares Available for Grant [Roll Forward]
Available at beginning of period (shares)	4,037
Newly authorized by Board of Directors (shares)	3,056
Stock options granted (shares)	(665)
Restricted stock units granted (shares)	(1,085)
Expired options under Stock Plans (shares)	95
Forfeited options under Stock Plans (shares)	65
Forfeited restricted stock units under Stock Plans (shares)	105
Available at end of period (shares)	5,608

COMMON STOCK OFFERING, RESTRI_6

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Assumptions of Fair Value of Stock Option Grants (Details)	6 Months Ended
	Jun. 30, 2021$ / shares
Share-based Payment Arrangement [Abstract]
Expected life (in years)	6 years
Volatility (as a percent)	41.00%
Dividend yield (as a percent)	0.00%
Risk-free interest rate (as a percent)	0.86%
Fair value per common share on date of grant (USD per share)	$ 7.61

COMMON STOCK OFFERING, RESTRI_7

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,478	$ 1,726	$ 4,711	$ 3,236
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	375	279	691	563
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	874	637	1,601	1,260
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,229	$ 810	$ 2,419	$ 1,413

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Deferred payroll tax payments	$ 3.3		$ 3.3
Federal statutory income tax rate (as a percent)	12.10%	27.00%	43.50%	27.30%

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2021USD ($)copyright	Jun. 30, 2020USD ($)	Mar. 31, 2017USD ($)	Jun. 30, 2021USD ($)copyright	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Sep. 15, 2020copyrightclient
Loss Contingencies [Line Items]
Employer contribution	$ 0.9	$ 0.7		$ 1.7	$ 1.3
Current carrying value of guarantor obligations	$ 12.8			12.8		$ 13.8
Oracle Litigation
Loss Contingencies [Line Items]
Damages awarded			$ 124.4	$ 89.9
Oracle Litigation II | Two Specific Company Clients
Loss Contingencies [Line Items]
Copyrights infringed | copyright							4
Number of clients | client							2
Oracle Litigation - Counterclaim
Loss Contingencies [Line Items]
Copyrights infringed | copyright	93			93
Amount awarded to other party				$ 35.4

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Jul. 31, 2018	Jun. 30, 2021	Jul. 19, 2018
Common Class A Stock
Related Party Transaction [Line Items]
New stock issued during period (shares)	400,000
Adams Street Partners
Related Party Transaction [Line Items]
Carrying value of preferred stock outstanding			$ 10
Adams Street Partners | Series A Preferred Stock
Related Party Transaction [Line Items]
New stock issued during period (shares)	19,209
Voting rights associated with shares of Series A Preferred Stock (shares)		12,319
Adams Street Partners | Common Stock
Related Party Transaction [Line Items]
Ownership of common stock outstanding (as a percent)		27.50%
Adams Street Partners | Common Stock | Voting control ownership
Related Party Transaction [Line Items]
Percentage of Common Stock under voting control (as a percent)		26.30%
Private Placements | Affiliated Entity
Related Party Transaction [Line Items]
Total consideration	$ 19.2

EARNINGS (LOSS) PER SHARE - Ear

EARNINGS (LOSS) PER SHARE - Earnings per share (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Temporary equity, conversion ratio			1
Net income	$ 6,807	$ 2,924	$ 3,231	$ 5,469
Cash dividends declared	(2,179)	(3,939)	(5,839)	(7,849)
PIK dividends declared	(654)	(1,181)	(1,752)	(2,354)
Accretion of discount	(804)	(1,567)	(2,277)	(3,114)
Net (loss) income after dividends and accretion	(4,846)	(3,763)	(14,691)	(7,848)
Undistributed earnings allocated using the two-class method	0	0	0	0
Net loss attributable to common stockholders	(4,846)	(3,763)	(14,691)	(7,848)
Net loss attributable to common stockholders	$ (4,846)	$ (3,763)	$ (14,691)	$ (7,848)
Weighted average number of shares of Common Stock outstanding (shares) | shares	85,343	68,290	82,056	68,076
Additional shares outstanding if Series A Preferred Stock is converted to Common Stock (shares) | shares	9,770	15,755	12,197	15,697
Total shares outstanding if Series A Preferred Stock is converted to Common Stock (shares) | shares	95,113	84,045	94,253	83,773
Percentage of shares allocable to Series A Preferred Stock (percent)	10.30%	18.70%	12.90%	18.70%
Weighted average number of shares outstanding, basic (shares) | shares	85,343	68,290	82,056	68,076
Weighted average number of shares outstanding, diluted (shares) | shares	85,343	68,290	82,056	68,076
Basic (usd per share) | $ / shares	$ (0.06)	$ (0.06)	$ (0.18)	$ (0.12)
Diluted (usd per share) | $ / shares	$ (0.06)	$ (0.06)	$ (0.18)	$ (0.12)
Series A Preferred Stock
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Return on repurchase of Series A Preferred Stock shares	$ 0	$ 0	$ (38)	$ 0
Accretion related to redemption of Series A Preferred Stock	(5,673)	0	(5,673)	0
Make-whole dividends related to redemption of Series A Preferred Stock	$ (2,343)	$ 0	$ (2,343)	$ 0

EARNINGS (LOSS) PER SHARE - Sum

EARNINGS (LOSS) PER SHARE - Summary (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income attributable to common stockholders, the diluted (shares)	4,208	2,182	4,460	2,279
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income attributable to common stockholders, the diluted (shares)	1,740	486	1,738	443
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income attributable to common stockholders, the diluted (shares)	1,682	1,696	1,862	1,836
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income attributable to common stockholders, the diluted (shares)	786	0	860	0

EARNINGS (LOSS) PER SHARE - Ant

EARNINGS (LOSS) PER SHARE - Antidilutive (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings (in shares)	37,111	43,948
Series A Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings (in shares)	8,716	15,491
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings (in shares)	3,556	3,322
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings (in shares)	6,711	7,007
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings (in shares)	18,128	18,128

FINANCIAL INSTRUMENTS AND SIG_3

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Narrative (Details) $ / shares in Units, $ in Thousands, shares in Millions	Jun. 20, 2019USD ($)	Mar. 07, 2019USD ($)	Jul. 19, 2018USD ($)	Jun. 30, 2021USD ($)year$ / sharesshares	Dec. 31, 2020USD ($)	Jun. 30, 2020USD ($)
Concentration Risk [Line Items]
Warrants outstanding (shares) | shares				18.1
Liability for redeemable warrants				$ 3,092	$ 2,122
Term to expirations (in years)				1 year 3 months 10 days
Property and equipment, net				$ 4,465	4,820
Operating lease right-of-use assets				15,772	17,521
Cash and cash equivalents				$ 110,387	87,575
Public Warrants
Concentration Risk [Line Items]
Warrants outstanding (shares) | shares				8.6
Exercise price of warrants (in USD per share) | $ / shares				$ 11.50
Non-US
Concentration Risk [Line Items]
Property and equipment, net				$ 1,200		$ 1,300
UNITED STATES
Concentration Risk [Line Items]
Operating lease right-of-use assets				10,100
INDIA
Concentration Risk [Line Items]
Operating lease right-of-use assets				5,200
Rest of the world
Concentration Risk [Line Items]
Operating lease right-of-use assets				400
Single Financial Institution
Concentration Risk [Line Items]
Cash and cash equivalents				84,600	50,200
Current restricted cash				$ 300	$ 300
Private Placement
Concentration Risk [Line Items]
Temporary stock issued	$ 2,997	$ 5,313	$ 126,763
Series A Preferred Stock | Private Placement
Concentration Risk [Line Items]
Temporary stock issued	$ 2,997	$ 5,313	$ 126,763
Measurement Input, Expected Term | Series A Preferred Stock | Minimum
Concentration Risk [Line Items]
Measurement input (as a percent) | year				4
Measurement Input, Expected Term | Series A Preferred Stock | Maximum
Concentration Risk [Line Items]
Measurement input (as a percent) | year				5
Measurement Input, Implied Yield | Series A Preferred Stock | Minimum
Concentration Risk [Line Items]
Measurement input (as a percent)				0.209
Measurement Input, Implied Yield | Series A Preferred Stock | Maximum
Concentration Risk [Line Items]
Measurement input (as a percent)				0.229
Measurement Input, Risk Free Interest Rate
Concentration Risk [Line Items]
Warrants and rights outstanding, measurement input (as a percent)				0.0012
Measurement Input, Risk Free Interest Rate | Series A Preferred Stock
Concentration Risk [Line Items]
Warrants and rights outstanding, measurement input (as a percent)	0.0172	0.0244	0.028
Measurement Input, Price Volatility
Concentration Risk [Line Items]
Warrants and rights outstanding, measurement input (as a percent)				0.588
Measurement Input, Price Volatility | Series A Preferred Stock
Concentration Risk [Line Items]
Measurement input (as a percent)				0.300

FINANCIAL INSTRUMENTS AND SIG_4

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue	$ 91,614	$ 78,402	$ 179,509	$ 156,434
United States of America
Disaggregation of Revenue [Line Items]
Revenue	49,562	47,376	97,121	94,822
International
Disaggregation of Revenue [Line Items]
Revenue	$ 42,052	$ 31,026	$ 82,388	$ 61,612

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)day	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)day	Jun. 30, 2020USD ($)
Lessee, Lease, Description [Line Items]
Days notice required to terminate (days) | day	30		30
Operating lease payments | $	$ 1.5	$ 1.5	$ 3	$ 3
Minimum
Lessee, Lease, Description [Line Items]
Operating lease renewal term (years)	1 month		1 month
Maximum
Lessee, Lease, Description [Line Items]
Operating lease renewal term (years)	5 years		5 years

LEASES - Components of lease ex

LEASES - Components of lease expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Operating lease expense related to ROU assets and liabilities	$ 1,546	$ 1,548	$ 3,100	$ 3,047
Other lease expense	132	297	292	615
Total lease expense	$ 1,678	$ 1,845	$ 3,392	$ 3,662

LEASES - Supplemental balance s

LEASES - Supplemental balance sheet information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease right-of-use assets, noncurrent	$ 15,772	$ 17,521
Operating lease liabilities, current	4,055	3,940
Operating lease liabilities, noncurrent	14,495	15,993
Total operating lease liabilities	$ 18,550	$ 19,933
Weighted average remaining lease term, operating leases (years)	4 years 4 months 28 days
Weighted average discount rate, operating leases (as a percent)	10.50%

LEASES - Maturities of lease li

LEASES - Maturities of lease liability (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 5,774
2023	5,198
2024	4,489
2025	4,002
2026	2,402
Thereafter	1,443
Total future undiscounted lease payments	23,308
Less imputed interest	(4,758)
Total	$ 18,550	$ 19,933